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ABSTRACT
Inflammation is considered to be the underlying cause of a majority of clinical
disorders. Thus, studies aimed at understanding the signaling pathways that trigger
inflammation could have significant translational impact. In the current study, we
investigated the effect of activation of cannabinoid (CB) and Aryl hydrocarbon
hydroxylase (AhR) receptors on the inflammatory response.

To that end, we used

cannabinoids such as ∆ (9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD), and a
well-established AhR agonist namely 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD).
These were tested against two inflammatory disease models: 1) Experimental
autoimmune encephalomyelitis (EAE), an animal model for human multiple sclerosis
(MS), and 2) Exposure to pertussis toxin (PTX), an exotoxin produced by the bacterium,
Bordetella pertussis, which causes whooping cough. We observed that combination of
THC and CBD resulted in attenuation of EAE clinical scores and reduced
proinflammatory cytokines secretion like IL-17A, IFN-γ, IL-6, TNF-α and IL-1β in the
mononuclear cells of the brain. Treatment of EAE mice with cannabinoids also led to
decrease in immune cell infiltration in the CNS, marked amelioration of CNS tissue
destruction, and reduced demyelination when compared to control mice. Additionally,
treatment with these cannabinoids led to cell cycle arrest and cell death in activated T
cells. MicroRNA (miRNA) microarray analysis, revealed altered miRNA profile in brain
infiltrating mononuclear cells following treatment with combination of THC and CBD
that promoted anti-inflammatory pathways. Interestingly, THC+CBD treatment of EAE
vi

mice caused alterations in gut microbiota with a decrease in the population of
Akkermansia muicinphila, the bacteria that are increased in MS patients and involved in
the pathogenicity of MS. In addition, THC+CBD treatment increased the production of a
wide range of short-chain fatty acids (SCFAs) that are anti-inflammatory. In mice treated
with PTX, there was significant induction of inflammation with an increase TH17 and
TH1 proliferation. AhR activation in PTX-treated mice with TCDD, led to increased
induction of FoxP3+ Treg cells and myeloid-derived suppressor cells (MDSC) that are
highly immunosuppressive. In addition, TCDD altered the expression of microRNAs that
promoted anti-inflammatory T cell phenotype. Together, the current study demonstrates
that activation of CB and AhR on immune cells leads to epigenetic modulations as well
as alterations in microbiota that promote anti-inflammatory signaling pathways. The
current study suggests that targeting CB and AhR constitutes a unique therapeutic
modality to treat inflammatory diseases.
.
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CHAPTER 1
INTRODUCTION
1.1 MULTIPLE SCLEROSIS
Multiple Sclerosis (MS) is the most autoimmune inflammatory disease of
autoimmune originate that affects the central nervous system (1-5). The demyelination
effect this disease causes to the sheath which covers the nerves, damages the signals
between the central nervous system (CNS) and the rest of the body, starting a massive list
of symptoms that patients with MS suffer from. The precise cause of MS is still
mysterious, yet its prevalence and incidence rates are increasing worldwide (6). It
believes that environmental, genetic factors, and exogenous are the primary agents
responsible for MS development (4). MS affects about 400,000 people in the US and
close to 2.1 million people worldwide (7). MS is three times prevalent in women than
men; it affects young people during their 20s and impairs their quality of life (7-9).
Symptoms that disturb the quality of life may include fatigue, depression, reduced
mobility, balance, numbness, pain, spasticity, cognitive impairment, dementia, vision ,
and bladder dysfunction(7). Several studies in Europe connect the mortality rate in
multiple sclerosis patients with suicide after they noticed that it increased compared to
other general populations (10). MS treatments that are available nowadays don’t show
any significant relief to the patients besides having immunotoxicity side effects (11).
Additionally, this disease is still a diagnostic challenge, and the lack of quick and
accurate diagnosis like the limited access to brain tissue could increase the cure challenge
1

(12). Currently, existing biomarkers for MS diagnosis and management have inherent
limitations; that is why additional new biomarkers are required (13). Although the
etiology of MS has not been uncovered yet, scientists found that CD4 T cells involved in
its pathogenicity (11). CD4+T cells infiltrate across the blood–brain barrier (BBB) and
promote inflammation, gliosis, neuroaxonal degeneration and demyelination leading to
disruption of neuronal signaling. CD4+T cells infiltrate across the blood-brain barrier
(BBB) and promote inflammation, gliosis, neuroaxonal degeneration, and demyelination
leading to disruption of neuronal signaling. Differentiated CD4+ T helper 1 (TH1) and
TH17 cells can infiltrate the CNS, leading to inflammation and tissue damage. In
multiple sclerosis murine model, experimental autoimmune encephalomyelitis (EAE):
emulsified central nervous system antigen is administered along with immune stimulants,
leading to the generation of pathogenic CD4 T helper 1 (TH1) cells and TH17 cells in the
lymph nodes. These cells then enter the circulation and eventually exert their effector
functions in the CNS. CD4+ TH1 and TH17 cells then trigger the production of proinflammatory cytokines and chemokines that initiate the inflammatory response in the
CNS.
1.2 MARIJUANA/CANNABINOIDS
Marijuana Cannabinoids are active components of Cannabis sativa, an annual
herbaceous plant they have been used by many cultures for centuries in medicine (14-17).
Many studies have been done to investigate the active role of these components and
others extracted from this plant. Studies showed the anti-inflammatory and
neuroprotective effects of Cannabinoids, which are effective in the treatment of several
autoimmune diseases, such as MS (16, 18-20). It has been reported that more than 400
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chemical components have been extracted from Cannabis Sativa, 80 of them find only in
this plant, and they don't in any other plant. Also, over 60 components are cannabinoids
(21). ∆(9)-Tetrahydrocannabinol (THC) is one of the major psychoactive constituents of
cannabinoids derived from the Cannabis sativa plant and is known for its antiinflammatory properties(22, 23). THC is well known for its immunoregulatory
properties. Precisely, regarding T cell activation, THC treatment has been shown to
reduce proinflammatory cytokines, including TNF-α and IFN-γ, and suppress
proliferation of T cells through apoptosis and induction of regulatory immune cells (2426). Also, THC is highly effective as a treatment in many models of T cell-driven
inflammatory diseases, including autoimmune hepatitis, allogeneic hematopoietic cell
transplantation, and inflammatory lung injury.(22, 26, 27).
CBD is another important cannabinoids component, a non-psychoactive cannabinoid
that might be used to moderate effects of THC in the therapeutic setting by providing
protection from the acute and permanent cognitive effects of THC (28). CBD has been
shown to exhibit anti-inflammatory properties (29). After many clinical trials, the
combined of THC and CBD oral/mucosal spray Sativex was approved in Canada for
spasticity that associated with multiple sclerosis (23, 30-32). Using marijuana,
particularly THC and CBD for therapeutic purposes continues to expand where there is a
growing scientific evidence for specific applications in autoimmune diseases like
multiple sclerosis (23). Studies showed that THC exerts its effects through CB1and CB2
receptors (15). Unlike THC, CBD does not bind and activate CB1 and CB2 receptors
because CBD itself has no affinity for these receptors, but it can act as a negative
allosteric modulator of CB receptors (20). Also, CBD has been shown to activate other

3

receptors such as 5-HT(1A), TRPV1 or GPR55. Both CB1 and CB2 are coupled to Gproteins where CB1 receptor presents in the central nervous system as well in the
immune cells, while CB2 receptor represents in specific peripheral tissues, mainly the
immune cells. THC shows its immunomodulated effect through CB1 and CB2 receptors,
but CBD works indirectly through CB2 receptor (20).
1.3 THE ENDOCANNABINOID SYSTEM
Endocannabinoids are a collection of bioactive lipids that might help as secondary
modulators, which when mobilized coincident with first-line immune modulators, either
increase or decrease many immune functions. Endocannabinoids lipid mediators are Narachidonoylethanolamine (anandamide, AEA) primarily isolated from porcine brain and
2-arachidonoylglycerol (2-AG) primarily isolated from canine intestines, which are the
first to be discovered and extensively studied (33-35). Additionally, they considered as
endogenous ligands for the cannabinoid receptors, CB1, and CB2 (36).

AEA is

responsible for preserving basal endocannabinoid signaling, binding to both the CB1 and
CB2 receptors. In contrast to AEA, 2-AG functions as a full agonist for both CB1 and
CB2. Furthermore, Anandamide and 2-arachidonyl glycerol (2-AG) bind to G proteincoupled cannabinoid receptors CB1 and CB2, respectively. These mediators show the
immunosuppressive effect of cannabinoids.
1.4 MICRORNAS
MicroRNAs (miRNAs) are short non-coding, single-stranded regulatory RNAs (on
average, 22 nucleotides in length) that regulate gene expression at the post-transcriptional
level (33, 34). miRNA bind primarily to the 3′-UTR of their respective target mRNA,
causing in translational repression or mRNA degradation, leading to a reduction in
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encoded protein (35, 36). miRNAs have developed much attention because they control
the expression of up to 30% genes and may play an essential role in the development of
many complex diseases (9). Recent studies showed that miRNAs play important roles in
a variety of physiologic and pathologic processes, most notably autoimmune diseases and
cancer (37, 38). Several studies have demonstrated a role for miRNA in modulating
immune responses under various inflammatory diseases (26, 39). miRNA dysregulation
may contribute to the pathogenesis of multiple sclerosis (40). Identification of novel
biomarkers and targets, for example, microRNAs, is beneficial to understand the
pathogenetic mechanisms in a disease such as multiple sclerosis (41). Keller et al. found
that the miRNA expression profiles in blood cells may serve as a biomarker for MS, and
deregulation of miRNA expression may play a role in the pathogenesis of this disease
(42). Moreover, mice deficient in miR-155 are resistant to developing experimental
autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis while the
overexpression of miR-155 exacerbates the symptoms associated with the disease (19)
(13). Collectively, these studies strongly suggest that miRNAs play a principal role in
controlling immune cell activation, mostly T cells, in addition to promoting
proinflammatory responses (26).
1.5 MICROBIOME AND MULTIPLE SCLEROSIS
Several environmental factors can affect immune function. Human healthy flora
consists of bacteria, fungi, yeast, archaea, viruses, helminths, protozoa and parasites, that
are mostly circulated in the internal cavity of our body, such as body surface, respiratory
tract, digestive tract, urogenital tract, more than 95% of them situated in the large
intestine (43, 44). The microbiota has an essential role in the initiation, training, and
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function of the host immunity (45). Furthermore, the commensal flora has significant
effects on the control of systemic inflammation and the development of autoimmune
disorders in animal models (43). Specifically, Gut microbiome dysbiosis has been
demonstrated to significantly influence a range of disorders in humans, including
rheumatoid arthritis, diabetes, obesity, and multiple sclerosis (MS)(46). MS is a complex
neural disease and still not fully understood etiology (6, 47). Whereas certain genetic and
environmental factors are involved (48). Changed gut microbiota might be one of the
main missing ecological factors contributing to MS since evidence recommends that
certain gut microbiota might be connected to either disease susceptibility or defense (4953). Furthermore, Studies found that metabolic deviation and alterations in the
intracellular levels of specific metabolites are linked to the inflammatory phenotype of
immune cells involved in autoimmune disorders such as rheumatoid arthritis, systemic
lupus erythematosus, diabetes and multiple sclerosis (MS) (54). Short-chain fatty acids
(SCFAs), the primary metabolites produced by bacterial fermentation of dietary fiber in
the gastrointestinal tract, are estimated to have a critical role in microbiota-gut-brain
linking(55). In recent years, the gut microbiota and fermentative metabolites like short‐
chain fatty acids (SCFAs) have received increased attention in relation to the
development and disease course of MS (56, 57). Additional investigations are required to
clarify the involvement of the gut microbiota and its metabolites, including potential
useful effects of SCFAs, in the development and course of MS.
1.6 PERTUSSIS TOXIN AND INFLAMMATION
Pertussis toxin (PTX) is a multisubunit protein toxin excretes exclusively by
Bordetella pertussis and it is one of the most potent virulence factors of this pathogen
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besides the adenylate cyclase toxin. Bordetella pertussis is the bacterial agent of the
pertussis disease or whooping cough (59). PTX is conveyed across the bacterial outer
membrane via a type IV secretion system encoded by the ptl genes (58, 59). PTX has a
broad range of effects on host cell activities because of its inhibitory effect on G-proteincoupled receptor pathways (60). During the peak of pertussis disease, and due to the PTX
activity, the gene expression of IL-17, TNF-α and IFN-γ was up-regulated, demonstrating
a mixed Th1 and Th17 cells response (61). Additionally, PTX has a role in autoimmunity
where it involves in exacerbating certain experimental autoimmune diseases in rodent
models, like Experimental Autoimmune Encephalomyelitis (EAE), the animal model of
multiple sclerosis in humans (62). PTX increases in the permeability of the blood-brain
barrier to allow the autoreactive T cells access to the central nervous system, initiating
EAE pathology (63). Furthermore, PTX induces IL-6 and IFN-γ production and enhance
the generation of Th17 cells to boost EAE effects (64-66).
1.7 AHR AND ROLE IN IMMUNE MODULATION
The aryl hydrocarbon receptor (AhR) is a transcription factor best known as the
ligand for the toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). However, it also binds
to other toxins and to endogenous ligands. Using gene expression profile analysis, murine
Th17 cells were shown to express the AhR which is also an essential component in the
development of both regulatory T cells (Treg) and Th17 responses resulting in increased
expression of IL-17 and IL-22 by Th17 cells (67). In another study, the AhR was shown
to directly regulate Foxp3 expression via a mechanism involving modulation of TGF-β
signaling (68)
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1.8 TCDD (2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN)
It is an extremely toxic environmental pollutant with a specific epigenetic
carcinogen and a potential tumor promoter effects (69).TCDD belongs to the halogenated
aromatic hydrocarbons compounds(70). TCDD is the most potent AhR agonist because
of its strong binding affinity (Kd 10−10–10−9 M) and resistance to metabolism (71). The
aryl hydrocarbon receptor (AhR) was the first TCDD receptor to be studied (5). The aryl
hydrocarbon receptor (AhR) is a significant cytosolic, ligand-activated receptor
represented by different cells in many mammals.(72, 73). The AhR belongs to basic
helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) transcription factor families(5). AhR gene
encodes a ligand-activated transcription factor over binding to halogenated aromatic
hydrocarbons (HAHs) such as TCDD, as well as polynuclear aromatic hydrocarbons
(PAHs) cause transformed gene expression and toxicity(74, 75). The AhR is necessary
for T cells to generate Foxp3+ Treg cells(76). Also, AhR is critical for the formation of
Tr1 cells in mice and humans, which inhibits autoimmune responses by interaction with
the transcriptional factor macrophage-activating factor to improve the expression of IL10, IL-21, and IL-27(77). Additionally, AhR stimulation is involved in the promotion of
Th17 to Tr1 transdifferentiation (78).
1.9 HYPOTHESES
In the current study, we tested the central hypothesis that inflammation can be
regulated through activation of CB receptors and AhR. To that end, we used two models
of inflammation:

EAE and PTX and used specific ligands for CB receptors

(cannabinoids) and AhR (TCDD) to study epigenetic pathways involving miRNA, and
microbiota that may help regulate inflammation. The specific hypotheses tested include:
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1.9.1. Combination of cannabinoids, Δ9- tetrahydrocannabinol (THC) and cannabidiol
(CBD) can ameliorate experimental autoimmune encephalomyelitis:
1.9.1.1. Through modulation of the systemic or local pro/anti-inflammatory cytokine
balance.
1.9.1.2. By promoting cell cycle arrest and apoptosis in activated T cells through
miRNA signaling pathways.
1.9.1.3. By altering the gut microbiome.
1.9.2. AhR activation can attenuate PTX-mediated systemic inflammation and regulation
of the immune response occurs:
1.9.2.1. Through modulation of the systemic pro and anti-inflammatory cytokine balance.
1.9.2.2. By suppressing Th17 cell proliferation and induction of Treg production through
miRNA signaling pathways.
The subsequent chapters are dedicated to test these hypotheses
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CHAPTER 2
COMBINATION OF CANNABINOIDS, Δ9 TETRAHYDROCANNABINOL AND CANNABIDIOL,
AMELIORATES EXPERIMENTAL MULTIPLE SCLEROSIS BY
SUPPRESSING NEUROINFLAMMATION THROUGH
REGULATION OF MIRNA-MEDIATED SIGNALING PATHWAYS
2.1 ABSTRACT
Multiple sclerosis (MS) is a chronic and disabling disorder of the central nervous
system (CNS) characterized by neuroinflammation leading to demyelination. Recently a
combination of Δ9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) extracted from
Cannabis has been approved in many parts of the world to treat MS-related spasticity.
THC+CBD combination was also shown to suppress neuroinflammation, although the
mechanisms remain to be further elucidated. In the current study, we demonstrate that
THC+CBD combination therapy (10mg/kg each) but not THC or CBD alone, attenuates
murine

experimental

autoimmune

encephalomyelitis

(EAE)

by

reducing

neuroinflammation and suppression of Th17 and Th1 cells. These effects were mediated
through CB1 and CB2 receptors inasmuch as, THC+CBD failed to ameliorate EAE in
mice deficient in CB1 and CB2. THC+CBD treatment also caused a decrease in the
levels of brain infiltrating CD4+ T cells and pro-inflammatory molecules (IL-17, INF-γ,
TNF-α, IL-1β, IL-6, and TBX21), while increasing anti-inflammatory phenotype such as
FoxP3, STAT5b, IL-4, IL-10 and TGF-β. Also, the brain-derived cells showed increased
apoptosis along with decreased percentage in G0/G1 phase with increased percentage in
10

G2/M phase of cell cycle. miRNA microarray analysis of brain-derived CD4+ T cells
revealed that THC+CBD treatment significantly down-regulated miR-21a-5p, miR-315p, miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p while
upregulating miR-706-5p and miR-7116. Pathway analysis showed that majority of the
down-regulated miRs targeted molecules involved in cycle arrest and apoptosis such as
CDKN2A, BCL2L11, and CCNG1, as well as anti-inflammatory molecules such as
SOCS1 and FoxP3. Additionally, transfection studies involving miR-21 and use of
Mir21-/- mice suggested that while this miR plays a critical role in EAE, additional miRs
may also be involved in THC+CBD-mediated attenuation of EAE. Collectively, this
study suggests that combination of THC+CBD suppresses neuroinflammation and
attenuates clinical EAE development and that this effect is associated with changes in
miRNA profile in brain-infiltrating cells.
2.2 INTRODUCTION
Multiple Sclerosis (MS) is chronic autoimmune disease that affects the central
nervous system (CNS)(79-81). The incidence of MS is higher in women who are affected
twice as often as men (82). Although the exact etiology of MS remains obscure,
observational research has suggested that genetic and environmental factors may cause
the onset and progression of the disease (83). Typically, MS is regarded as a T cell
mediated autoimmune disorder, primarily driven by inflammatory Th1 and Th17 cells
(83), (84). When autoreactive T-lymphocytes cross the blood brain barrier (BBB) and
enter the central nervous system, they initiate local inflammation that results in
demyelination, gliotic scarring, and axonal damage (85)
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Cannabinoids extracted from marijuana (Cannabis sativa), as well as synthetic
forms have been well characterized for their anti-inflammatory properties (15).
Cannabinoids have also been shown to ameliorate spasticity and neuropathic pain in MS
patients (86), (87). It is for this reason, a combination of Δ9 - tetrahydrocannabinol
(THC) and Cannabidiol (CBD) has been approved as a drug (Sativex) in several countries
including Europe, Australia and Canada (88). THC and CBD combination was tested
recently in animal models of MS and was found to suppress neuroinflammation (89),
(90). However, the precise mechanisms, such as the role of miRNA, in the efficacy of
such combination treatment remain to be elucidated further. (THC) is well known for its
psychoactive properties. It acts through CB1 receptors primarily expressed in the CNS
and CB2 expressed predominantly on immune cells (91). Our laboratory and others
have shown that THC increases anti-inflammatory and decreases pro-inflammatory
cytokine production (16, 22, 26, 92) THC also mediates apoptosis in T cell driven
inflammation, increases FoxP3+ Tregs through miRNA induction and epigenetic
modifications(22, 26). On the other hand, CBD is a non-psychoactive phytocannabinoid,
has also been shown to exhibit anti-inflammatory properties (29).

CBD has recently

been approved by US FDA as a drug to treat epilepsy (91). Unlike THC, CBD does not
bind and activate CB1 and CB2 receptors but can act as a negative allosteric modulator of
CB receptors (93). Also, CBD has been shown to activate other receptors such as
GPR55, TRPV1 or 5-HT1a (18, 94, 95). Thus, it is possible that a combination of
THC+CBD may be more effective in treating inflammation by targeting both
cannabinoid CB1 and CB2 receptors as well as other potential receptors such as GPR55,
TRPV1 or 5-HT1a.
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MicroRNAs (miRNA, miR) are a class of short non-coding single-stranded RNAs
19-24 nucleotides in length, involved in the post-transcriptional regulation of gene
expression (81, 96, 97). miRNAs exert their regulatory role when they bind to the 3′
untranslated region (UTR) of target mRNA, eventually causing translational suppression
through degradation or sequestration of mRNA (98) Several studies have detected the
involvement of circulating miRNAs in physiological and pathological processes and
identified them as potential biomarkers, therapeutic agents, or drug targets (99).
Numerous miRNAs were found to be differentially expressed in patients with MS
compared with controls and to have the potential to be used as diagnostic biomarkers or
predictors of drug-response (100). Additionally, recent studies have shown crucial roles
of specific miRNAs in controlling oligodendrocyte (OL) differentiation and myelination
(101)

Dysregulation of miRNAs contributes to the pathogenesis of demyelinating

diseases (102) . Moreover, new patents of miRNAs also provide new strategies for gene
therapy and miRNA-drug development for demyelinating diseases, especially MS (103).
Our lab has previously shown that cannabinoids can suppress inflammation in the
periphery through regulation of miRNA(16) (81, 104). However, whether cannabinoids
can alter the expression of miRs in the brain-infiltrating cells during EAE and whether
such miRs contribute towards suppression of neuroinflammation has not been
investigated. In the current study, we used the combination of cannabinoids, THC and
CBD, to address the potential ability of these components in ameliorating the symptoms
and the progression of the disease in the EAE model, a murine model of MS. We
demonstrate for the first time that the neuroprotective and anti-inflammatory properties of
THC+CBD can be attributed to their ability to induce cell cycle arrest and apoptosis in
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activated T cells as well as a switch of cytokines from pro-inflammatory to antiinflammatory, through altered expression of miRNAs.
2.3 MATERIALS AND METHODS
Mice
C57BL/6 female mice aged 6-8-week-old and Mir21-/- mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). CB1-/-CB2-/- mice were bred in-house. Mice
were housed in a specific-pathogen-free facility at the University of South Carolina
School of Medicine. All animal experiments were ethically performed according to the
NIH guidelines and protocols approved by the University of South Carolina Institutional
Animal Care and Use Committee.
Reagents
The reagents used in this study were purchased as described: THC and CBD from
Cayman Chemical (Michigan. USA), myelin oligodendrocyte glycoprotein (MOG35-55)
peptide H-MEVGWYRSPFSRVVHLYRNGK-OH (PolyPeptide Laboratories, San
Diego, CA, USA). Mycobacterium tuberculosis (strain H37Ra) (BD, Franklin Lakes, NJ,
USA), complete Freund’s adjuvant (Fisher, Hampton, NH, USA), Pertussis toxin (List
Biological Laboratories, Campbell, CA, USA), Percoll, GE Healthcare Life Sciences
(Pittsburgh, PA.USA); Neural Tissue Dissociation Kit (P) (Miltenyi Biotech, Auburn,
CA.USA), RBC lysis buffer (Sigma-Aldrich, St. Louis, MO, USA), RPMI 1640, lglutamine, HEPES, phosphate-buffered saline, and fetal bovine serum (VWR, West
Chester, PA, USA), ELISA Max Kits IL-10, IL-17A, IFN-, IL-6, IL-1β, TNF-α and
TGF- and FITC Annexin V/ PI apoptosis kit (Biolegend, San Diego, CA). EasySep PE
selection kit (Stemcell Technologies, Cambridge, MA. USA), Propidium Iodide
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(PI)/RNase Staining Solution (Cell Signaling Technology, Danvers, MA, USA),
miRNeasy Mini Kit, miScript II RT Kit and miRNAs primers (Qiagen, Valencia, CA),
mRNAs

primers

(Integrated

DNA

technologies,

Coralville,

IA.

USA)

and

SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA, USA).
EAE induction, cannabinoid administration, and clinical assessment
EAE was induced in female C57BL/6 mice (6–8 weeks old) through subcutaneous
(s.c.) immunization in the hind flank with 100 μl of 150 μg MOG35-55 peptide
(PolyPeptide Laboratories San Diego, CA. USA) emulsified in complete Freund’s
adjuvant (Fisher, Hampton, NH, USA) containing 8 mg/ml killed Mycobacterium
tuberculosis (strain H37Ra) (BD, Franklin Lakes, NJ, USA), as described previously(104,
105) Following immunization, 200 ng of pertussis toxin (List Biological Laboratories,
Campbell, CA.USA) was given to the mice by intraperitoneal injection on day 0,
followed by 400ng on day 2. Control mice received CFA+PTX but not MOG. To study
the effect of THC+CBD treatment mice were randomized and treated with 10 mg/kg each
THC and CBD or vehicle (2% dimethyl sulfoxide (DMSO) + 20% EtOH) diluted with
sterile 1X PBS i.p. starting on day 10 after immunization and this treatment continued
every day until the end of the experiment. Monitoring the animals and recording the
clinical scores were done on a daily basis during the experiment. The mean of the score
was calculated for each group every day. Clinical scores were recorded as follow: 0,
healthy; 1, flat tail; 2, partial paralysis of hind limbs; 3, complete paralysis of hind limbs
or partial hind and front limb paralysis; 4, tetraparalysis; 5, moribund; 6, death (106).
Mice were provided daily with food and water (Boost and Hydrogel) in the cage floor
after appearance of symptoms to ensure access to essential nourishment.
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Nociception assay
Nociception is considered as one of the clinical markers of EAE(107). In the
current study, we used the hot plate test to investigate nociception in unrestricted mice by
placing each mouse on a platform surface which was maintained at 50°C. The response
latency, which is the time taken to observe a nocifensive behavior that includes forepaw
withdrawal or licking, hind paw withdrawal or licking, stamping, leaning posture and
jumping, was recorded (108).
Histopathology
Perfused spinal cord tissues were isolated at 15 days post MOG immunization.
Tissues were immersed in 4% paraformaldehyde for 24hr. Then paraffin blocks were
prepared. Microtome sections (7 μm) were cut, and tissue sections were stained with
Luxol Fast Blue (LFB) for detection of demyelination, in addition to haemotoxylin and
eosin (H&E) staining for visualization of cellular infiltration. The images were acquired
by Cytation 5 imaging reader (BioTek).
Isolation of immune cells
On day 15 post MOG immunization, inguinal lymph nodes (iLN) were excised
from, EAE+Vehicle and EAE+(THC+CBD) prior to perfusion and were processed
immediately to prepare single-cell suspensions. Then, mice were perfused slowly with 10
mL heparinized PBS to get rid of contaminated blood. Whole brain tissues were isolated
then homogenized separately into a single-cell suspension by using the Neural Tissue
Dissociation Kit (P) (Miltenyi Biotech, Auburn, CA.USA) and red blood cell lysis buffer
(Sigma-Aldrich, St. Louis, MO.USA). Mononuclear cells (MNC) from whole brain
homogenates were then isolated by centrifugation in media containing 33% (v/v) isotonic
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Percoll in FACS buffer (1X PBS, 2% heat-inactivated fetal bovine serum) (GE
Healthcare Life Sciences, Pittsburgh, PA, USA). Cells were immediately counted and
processed for further assays.
Cell culture
Brain MNCs and splenocytes cells were cultured for 24h in complete RPMI 1640
media supplemented with 10% heat-inactivated fetal bovine serum, 10 mM l-glutamine,
10 mM HEPES, 50 μM β-mercaptoethanol (Sigma-Aldrich St. Louis, MO.USA), and
100 μg/ml penicillin/streptomycin at 37°C, 5% CO2, 95% humidity (104). Cell culture
supernatants were collected for ELISA and/or cells were processed for flow cytometry,
apoptosis and cell cycle assays.
Detection of cytokines
Brain and iLN were isolated from EAE+VEH and EAE+(THC+CBD) mice and
processed to obtain single-cell suspensions, and 1 x 106 cells were cultured for 24 hours
at 37°C, 5% CO2, 95% humidity as described (104). Cell culture supernatants were
processed to detect interferon-γ (IFNγ), interleukin-17A (IL-17A), interleukin-6 (IL-6),
Tumor Necrosis Factor-α (TNFα), interleukin 1β (IL-1 β), interleukin-10 (IL-10) and
transforming growth factor- (TGF-) using ELISA kits following the manufacturer’s
instructions (BioLegend, San Diego, CA). Absorbance at 450nm was read on a plate
reader and concentrations were calculated using standard curves.
Antibodies and flow cytometry
Cells were stained with fluorochrome-conjugated antibodies and analyzed via BD
FACS Celesta (San Jose, CA) to determine phenotypes of infiltrating brain mononuclear
cells. Antibodies used: fluorescein isothiocyanate (FITC) -conjugated anti-CD3 (clone:
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145-2C11), Brilliant Violet (BV785)-conjugated anti-CD4 (clone: GK 1.5), from
Biolegend (San Diego, CA).
Detection of (THC+CBD)-induced apoptosis in brain MNCs
To determine if (THC+CBD) induces apoptosis in brain MNCs, cells were purified
and cultured as described (104). After 24 hr incubation, cells were collected and washed
twice with ice-cold 1X PBS, and then resuspended in Annexin V Binding Buffer at a
concentration of 0.25-1.0 x 107 cells/ml. Next, 100 µl of cell suspension was transferred
to a 5 ml flow tube. Next, 5 µl of FITC Annexin V and 10 µl of Propidium Iodide
Solution was added. The cells were gently vortexed and incubate for 15 min at room
temperature in the dark. Finally, 400 µl of Annexin V Binding Buffer was added to each
tube and analyzed by flow cytometry (BioLegend, San Diego, CA. USA).
Cell cycle analysis
Brain MNCs were cultured as described (104) . Cells were collected and stained
with the PI/RNAs staining following the manufacturer’s instructions (Cell Signaling
Technology, Danvers, MA. USA). The data were acquired by flow cytometry and
analyzed with ModFit LT 3.3 (Verity Software House, Topsham, ME) after debris and
doublets were gated out.
CD4+ T cell selection
Brain MNCs were labeled with Phycoerythrin (PE)-conjugated anti-CD4 (Clone:
GK 1.5) antibody (BioLegend, San Diego, CA) then immunomagnetically selected with
EasySep PE-positive selection kit according to the manufacturer instructions (StemCell
Technologies, Vancouver, BC). After selection, the purity of selected CD4 was measured
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by flow cytometry which was routinely > 90%. CD4+ T cells were lysed in Qiazol and
stored at -80°C until RNA isolation (Qiagen).
RNA isolation and cDNA synthesis
Total RNA was purified from brain CD4+ T cells by using miRNeasy micro kit
according to the manufacturer instructions and the concentration and purity of RNA were
determined using the NanoDrop 2000 spectrophotometer from Thermo Scientific
(Wilmington, DE). Next, the expression profiling of miRNAs using the Affymetrix
GeneChip miRNA 4.0 array platform was performed as previously described (109)(. To
validate miRNAs expression, the miScript cDNA synthesis kit used followed by
quantitative real-time polymerase chain reaction (qRT-PCR) using the miScript SYBR
Green PCR kit. Fold change of the interested miRNAs was determined using the 2-ΔΔCt
method and expressed relatively to Snord96a. (Bio-Rad, Hercules, CA, USA). Validation
of target genes expression, primers were purchased (Integrated DNA technologies,
Coralville, IA. USA) and quantitative real-time polymerase chain reaction (qRT-PCR)
was performed using SsoAdvanced universal SYBR Green supermix (Bio-Rad, Hercules,
CA, USA). Fold change of the interested mRNAs was determined using the 2-ΔΔCt
method and expressed relative to GAPDH.
Transfection with miR-21a-5p mimic and inhibitor
Splenic CD4+ T cells were purified by using the EasySep PE selection kit. The
purity of the isolated cells was confirmed to be 97% CD4+ T cells by flow cytometry.
Then cells were maintained for 24 hours in complete RPMI 1640 media supplemented
with 10% heat-inactivated fetal bovine serum, 10 mM l-glutamine, 10 mM HEPES, 50
μM β-mercaptoethanol, and 100 μg/ml penicillin/streptomycin at 37°C and 5% CO2 (22)
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Cells were seeded at 2 × 105 cells/well in a 24-well plate and transfected for 24 hours
with mock control or 40 nM synthetic mimic or inhibitor oligonucleotides using
HiPerFect transfection reagent (Qiagen, Germantown, MD) according to the
manufacturer’s instructions. Total RNA and protein were extracted for analysis.
Statistical analysis
We performed statistical analysis using GraphPad Prism 8 (GraphPad Inc, La Jolla,
CA). The data shown in this study represent at least three independent experiments to
ensure consistency of findings. The statistical differences between groups were calculated
using Student’s t-test for paired analyses or one- or two-way ANOVA for multiple group
analyses. Mann–Whitney U test was performed to evaluate the extended clinical scoring
in EAE mice, as described (104, 110). Statistical tests with post hoc tests are indicated in
each figure legend. A p value of ≤0.05 was considered significant.
2.4 RESULTS
Combination of THC and CBD attenuate the development of EAE
Combination of THC+CBD has been used to treat human MS (111). This treatment
is known to decrease not only muscle spasticity but also suppress neuroinflammation (89,
90). To further investigate the mechanisms of suppression of neuroinflammation, we used
murine model of EAE. Mice were treated daily with THC alone (10mg/kg), CBD alone
(10mg/kg), or a combination of THC+CBD (10mg/kg each) starting at 8-10 days after
MOG immunization (Figure 1A). Use of CFA+PTX as a control did not trigger any
clinical signs of paralysis and furthermore, treatment of these mice with cannabinoids did
not have any effect, thereby showing that the subsequent studies reported on EAE
development using MOG was antigen-specific. Thus, in all subsequent experiments, we
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used CFA+PTX+MOG to induce EAE and study the effect of cannabinoids. The
combination THC+CBD treatment resulted in attenuation of the clinical symptoms of
EAE vs mice treated with Vehicle (VEH) (Figures 1C & 1D). Also, treatment with THC
or CBD alone, at the doses tested, failed to cause significant suppression of clinical
symptoms. On day 14, the clinical scores were significantly reduced only in THC+CBD
group but not in THC or CBD alone groups (Figure 1D). These results indicated that the
combination of THC+CBD was effective to treat mice with EAE. Based on these data,
we focused our subsequent studies to combination treatment only. Thus, an extension of
the experiment until day 27 demonstrated that THC+CBD treatment was highly effective
long-term at reducing clinical signs of EAE (Figures 1E & 1F).
Next, we performed histological analysis on spinal cord tissues harvested at day 15.
The spinal cord tissues from EAE+VEH mice showed elevated cellular infiltration vs
Naïve mice when stained with H&E (Figure 1G). Also, extensive demyelination was
observed in the white matter area with LFB staining in EAE+VEH vs Naïve mice (Figure
1G). Both cellular infiltration and demyelination were reduced in spinal cord tissue of
EAE+(THC+CBD) mice (Figure 1F). To test the role of CB1 and CB2 receptors in our
model, we induced EAE in both wild-type (WT) and CB1-/-CB2-/- double-knockout mice,
and then treated with THC+CBD. Absence of cannabinoid receptors resulted in the
inability of THC+CBD to reduce clinical scores of EAE (Figures 1H & 1I). The hot plate
test was also performed to test the pain response and WT EAE+(THC+CBD) mice had
increased withdrawal latency period indicating that cannabinoid receptor activation with
THC+CBD had analgesic effects as well (Figure 1J).
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Treatment with THC+CBD attenuates T-cell mediated inflammation in draining
lymph nodes and brain
Cell culture supernatants were isolated from draining iLN cells isolated at the peak
of the disease. The cells were cultured at equivalent cellular density for 24hr and
supernatants were assessed for the Th17 and Th1 pro-inflammatory cytokines, IL-17A
and IFNγ, respectively. THC+CBD treatment reduced production of IL-17A and IFNγ in
iLN (Figure 2A).

Additionally, flow cytometry analysis of encephalitogenic

mononuclear cells (MNC) isolated from brain tissue showed decreases in the populations
of total MNCs, CD3+ T cells, and of CD3+CD4+ Th cells in the EAE+(THC+CBD)
group when compared to other experimental groups (Figures 2B & 2C). Use of CB1 -/CB2-/- double-knockout mice showed that the effect of THC+CBD in decreasing
neuroinflammation was mediated through these cannabinoid receptors (Figures 2B & 2C)
because THC+CBD was ineffective in these mice.
miRNA analysis of THC+CBD treated EAE mice
Because miRNAs play an important role in autoimmune diseases and
neuroinflammation (112, 113), we investigated the role of miRNA in the THC+CBDinduced attenuation of neuroinflammation in EAE mice. To that end, brain CD4+ T cells
were isolated from mice treated with THC+CBD or vehicle as described earlier and used
for miR microarray analysis. Of approximately 2000 miRNAs tested, 157 miRNAs were
differentially expressed (Fold change > +/- 1.5) (Figure 3A). Proportional Venn diagram
was generated to represent the fold change of the miRNAs that were up- or downregulated following treatment with THC+CBD in EAE mice (Figure 3B). A heat map
generated showed different expression profile of miRNAs in the experimental groups
(Figure 3C). Pathway analysis of the differentially expressed miRNAs was performed
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with Ingenuity Pathway Analysis (IPA, Qiagen) and showed interaction with cell cycle,
apoptosis, and T cell polarization molecules (Figure 3D). The microarray data and
pathway analysis indicated several miRNAs that have been previously involved in the
pathogenicity of MS such as, miR-31, -21a, -146a, -155 and -33(41) Quantitative RTPCR validated that THC+CBD treatment led to downregulation miR-21a-5p, miR-31-5p,
miR-122-5p, miR-146a-5p, miR-150-5p, miR-155-5p, and miR-27b-5p (Figures 3E-3K).
These miRNAs were found to directly target IL-10, FoxP3, SOCS1, Bcl2L11 and
CCNG1 (Figure 3D and Table 1). THC+CBD treatment increased expression of miR706-5p and miR-7116 (Figure 3L-3M). The IL-17A gene was one of the hallmark genes
that is targeted by miR-706-5p (Figure 3D and Table 1). Genes encoding TNF-α and IL-6
were found to be targeted by miR-7116-5p (Figure 3D and Table 1). These genes play a
pivotal role in EAE progression. Putative 3’ UTR targeting was analyzed for each
miRNA-mRNA pairing using TargetScan alignment tools and microRNA.org (Table 1).
Collectively, these data indicated that microRNA may have an integral role in the
ameliorative effect of THC+CBD in EAE mice.
Cytokine expression at gene and protein levels in EAE brain MNCs
Pathway analysis identified miRNAs that targeted pro-inflammatory and antiinflammatory cytokines and Th subset transcription factors (Figure 3D). Expression of
these target genes was validated by qRT-PCR (Figures 4A-4K). Treg related genes
Foxp3, Stat5b, and IL10 were upregulated in EAE+(THC+CBD) brain-derived CD4+ T
cells (Figures 4A-4C). Th2 related genes Gata3 and Il4 were also upregulated in CD4+ T
cells following treatment (Figures 4D & 4E). Conversely, Th17 related genes Stat3 and
Il17a were downregulated following THC+CBD treatment (Figures 4F & 4G). Likewise,
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Th1 related genes Tbx21 (encoding Tbet) and Ifng were downregulated in
EAE+(THC+CBD) (Figures 4H & 4I). In addition, pro-inflammatory cytokines Il6 and
Il1b were downregulated (Figures 4J & 4K). Cell culture supernatant of mononuclear
cells from brain was used to evaluate cytokine production. In accordance with gene
expression changes, IL-17A, IFNγ, TNFα, IL-6, and IL-1β production was reduced, while
IL-10 and TGFβ production was increased in MNC supernatant from EAE+(THC+CBD)
mice (Figure 4L).
Detection of cell cycle arrest / apoptosis in brain MNCs
miRNA array and pathway analysis also revealed that some pro-apoptotic and cell
cycle arrest genes were targeted by downregulated miRs in EAE+(THC+CBD) mice
including CDKN2A, SOCS1, Bcl2L11, and CCNG1 (Figure 3D). We validated
upregulation of these genes by qRT-PCR (Figures 5A-5D). Fold change was expressed
relative to GAPDH. The primers used in the study are highlighted in Table 3. In addition,
PI staining demonstrated that WT EAE+(THC+CBD) mice, in brain MNCs, had less
cells in G0/G1 phase but more cells in G2/M phase of cell cycle when compared to WT
EAE+Veh group (Figures 5E &5F). We also used a combination staining of Annexin VFITC with PI double-staining to identify early apoptotic (AnnexinV+/PI-) and late
apoptotic cells (AnnexinV+/PI+). Late apoptosis was elevated in WT EAE-(THC+CBD)
(Figures 5G & 5H). In some of these experiments, we also used CB1-/-CB2-/- double
knockout mice to test if the action of THC+CBD was mediated through cannabinoid
receptors and we did find that to be true. However, these mice showed some changes in
apoptosis when compared to WT mice which can be explained by the fact that in these
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mice, endocannabinoids were not able to act or that these mice had some compensatory
mechanisms acting.
Mir21-/- mice are more resistant to EAE than wild-type mice
In our study, we found that THC+CBD treatment downregulated miR-21a-5p
expression in brain CD4+ T cells (Figures 3C-3E). To further address the role of this
miRNA, we performed an in vitro miRNA transfection assay in CD4+ T cells and used
qRT-PCR validation to test for miR-21 and target genes in cells transfected with mock,
mimic or inhibitor (Figures 6A-6D). The data showed that use of miR-21 mimic led to a
decrease in the expression of target genes while inhibitor caused significant induction of
the target genes. In addition, we also used mice deficient in miR-21. Genotyping for the
parents and the first generation of Mir21-/- mice (miR-21 KO) confirmed inactivation of
the miR-21 gene (Figure 6E). To test the role of miR-21 in THC+CBD-mediated
amelioration of EAE, we induced EAE in WT and Mir21-/- mice then treated with
THC+CBD when symptoms appeared. The clinical scores revealed that Mir21-/- mice had
less disease severity when compared with WT EAE mice (Figures 6F and 6G). Treatment
with THC+CBD in Mir21-/- mice further reduced clinical symptoms of EAE similar to
WT EAE+(THC+CBD) (Figures 6F & 6G). We performed cell cycle analysis in brain
MNCs stained with PI to detect cell cycle by flow cytometry. The EAE-induced Mir21-/mice were more similar to EAE+(THC+CBD) group in that these mice showed less cells
in G0/G1 phase and more cells G2/M phase and furthermore, THC+CBD treatment in
these mice failed to further cause significant changes in cell cycle thereby showing that
THC+CBD-mediated effects on cell cycle are mediated through miR-21 (Figures 6H-6I).
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Because Mir21-/- mice were more resistant to EAE when compared to WT mice,
these data suggested that miR-21 does play a critical role in EAE and therefore,
THC+CBD mediated down-regulation of miR-21 may play a role in cannabinoidmediated attenuation of EAE. However, when we treated Mir21-/- mice with THC+CBD,
we found that these mice exhibited further reduction in EAE thereby suggesting that
additional miRNAs may also be involved in the efficacy of cannabinoids to suppress
EAE.
2.5 DISCUSSION
MS is an immune-mediated inflammatory disease of the CNS (114, 115). The
precise mechanisms of pathogenesis of MS remain unknown, although environmental as
well as genetic components are believed to participate in this demyelinating disease(116)
Current treatments for MS often consist of immunosuppressive drugs with many sideeffects after prolonged use. In the current study, we investigated the role of miRNA in
the attenuation of EAE by a combination of cannabinoids, THC and CBD, and found that
such a treatment altered the expression of miRNA in brain MNCs that targeted
inflammatory pathways leading to decreased expression of inflammatory cytokines as
well as promotion of cell cycle arrest and apoptosis in encephalitogenic T cells in brain.
Recently, a combination of THC+CBD, extracted from Cannabis plant, named
Sativex, has been approved to treat MS in over 28 countries, including Europe and
Canada to help improve muscle spasticity(111, 117). It is noteworthy that in the current
study, while we used a combination THC and CBD, these were pure compounds, whereas
in Sativex, the THC+CBD extract from Cannabis also includes low levels potentially
other minor phytocannabinoids and terpenes, which may enhance the effects of
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THC+CBD, called the ‘entourage’ effect. Thus, this finding constitutes a limitation in
comparing our studies to Sativex. Nonetheless, our studies also demonstrate that pure
forms of THC+CBD can also serve as therapeutic modality in the treatment of MS. We
and others have shown that both THC and CBD are potent suppressors of inflammation
in a variety of autoimmune and inflammatory disease models (16, 26). Thus, it is likely
that THC+CBD combination can also suppress neuroinflammation, in addition to
suppressing muscle spasticity. In fact, recent studies demonstrated that THC+CBD
combination can attenuate EAE by suppressing neuroinflammation (89, 90)and our study
further supports this finding. It should be noted that we and others have shown that THC
and CBD when used alone, can suppress EAE (16, 19, 118, 119) In the current study, we
observed that CBD or THC when administered alone at 10mg/kg failed to suppress
clinical scores in MOG-induced EAE. We found in a previous study that a dose of
20mg/kg of CBD was necessary to attenuate clinical signs in EAE (16) . There are
limited studies on THC and the dose and efficacy may depend on the model of EAE, its
use as preventive or treatment measure, the strain/species model used and the like (120)
Nonetheless, we found in our current study, using cannabinoids after disease onset, that a
single dose of CBD or THC at 10 mg/kg was not effective while a combination of these
was highly effective in suppressing clinical symptoms and neuroinflammation in EAE. It
should be noted that in a previous study, the authors treated EAE mice with THC
(20mg/kg), CBD (20mg/kg) or THC+CBD (10mg/kg each), daily from the day symptoms
appeared till the first relapse of the disease and found that the three treatments delayed
the onset of symptoms. However, only THC+CBD or THC alone were able to attenuate
neurological disability while CBD failed. The difference between this study and the
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current study is that we used lower doses of THC or CBD alone (10mg/kg) and we
treated the mice for much shorter duration. The reason for the design of our study was to
identify the miRNA which would be induced early on and characterize them. Thus, it is
possible that if we had continued treatment with CBD or THC alone for the entire
duration of the study, we could have found these to be effective.
It is well-established that THC acts through CB1 and CB2 receptors while CBD
does not bind to these receptors or binds with very low affinity but in vivo, may act
through other receptors such as GPR55, TRPV1, 5-HT1a or PPAR-

(18, 94, 95)

(121),(90). Nonetheless, CBD can alter the uptake and breakdown of endocannabinoids
thereby indirectly affecting the activation of CB receptors or it can mediate CB1
antagonism (122, 123) In the current study, we used mice deficient in CB1 and CB2 and
found that these mice bearing EAE when treated with THC+CBD failed to exhibit EAE
amelioration which suggested that THC+CBD treatment was acting through these
receptors. However, these mice showed similar levels of clinical disease as the wild-type
mice. This may be because they may exhibit some compensatory mechanisms or that the
endocannabinoids in the absence of CB1 and CB2 may act on other receptors such as the
vanilloid receptors (124) To the best of our knowledge, there are no previous studies on
the use of such double-knockout mice in EAE. However, the use of mice deficient in
CB1 or CB2 alone has provided evidence for the involvement of these receptors and
endocannabnoids in EAE. For example, mice deficient in CB1 receptor showed a more
severe clinical course indicating that endogenous cannabinoids activate CB1 that helps
control neuroinflammation and EAE (125) Also, CB2 knockout mice were shown to
exhibit exacerbated EAE. However, pharmacological agonism or antagonism of CB2
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failed to affect EAE in ABH mice (126). Such studies have raised some concerns about
the translational value of some transgenic/gene knockout studies which may depend
on susceptibility genetic backgrounds (127). Additionally, the knockout mice may have
different microbiota which may influence EAE as shown in our studies in mice with
CD44 deletion (128)

Thus, clearly, additional studies are necessary on use of CB

receptor knock out mice in understanding the role of cannabinoids in EAE.

In the

current study, the anti-inflammatory properties of THC+CBD were evident in their ability
to decrease the expression of pro- inflammatory cytokines (IL-17A, IL-6, TNF-α, IFNγ
and IL-1β) induced in EAE. Also, Chalah MA et al. found that the pro-inflammatory
cytokines IL-6, TNF-α, and IFNγ are related to MS fatigue, which is one of the distinct
symptoms that the MS patients are suffering from(129) T-bet is a Th1 cell-specific
transcription factor that controls the expression of the hallmark Th1 cytokine, IFN-γ
(130) In our study we found that its expression was repressed along with other cytokine
transcription factors of IL-17A, IL-6 and TNF-α after treatment with the THC+CBD,
which demonstrate the inflammatory suppressive role of the cannabinoids. Increased
GATA-3 expression plays an important role in enhancing IL-4 production in
differentiated Th2 and inhibiting Th1 differentiation (131) On the other hand, we also
found that the cannabinoids increased the expression of the anti-inflammatory cytokines
(IL-10 and TGF-β). It has been reported that the deficiency or abnormal expression of
IL-10 can increase inflammatory response to microbial challenge but also lead to
development of inflammatory bowel diseases (IBDs) and several autoimmune diseases
(132, 133) Overall, our data are consistent with the previously reported studies
demonstrating that cannabinoids suppress cytokine production and promote Th2 while
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suppressing Th1 cells (22, 25, 134) Our previous studies have also identified the
mechanisms through which cannabinoids such as THC suppress cytokine production.
One of the mechanisms include epigenetic modifications in which THC treatment leads
to the association of active histone modification signals to Th2 cytokine genes and
suppressive modification signals to Th1 cytokine genes, leading to a switch from Th1 to
Th2 (135)
We have previously shown that miRNA play a critical role in cannabinoidmediated suppression of inflammation. In delayed-type hypersensitivity (DTH) model,
we noted that THC suppressed Th17 cell differentiation through suppression of miR-21
expression, which induced SMAD7 consequently suppressing Th17 (22) THC also
caused downregulation of miR-29b, an IFN-γ inhibitor. THC treatment reversed this miR
dysregulation. Additionally, when we transfected primary cells from DTH mice with
miR-21 inhibitor or miR-29b mimic, there was an increase in SMAD7 and decrease in
IFN-γ expression, respectively.

In the current study, we observed downregulation of

miR-155 in EAE mice treated with THC+CBD. Recent studies have focused on the
participation of miR-155 in EAE. MiR-155 mediates inflammatory response through
promoting the development of inflammatory Th1 and Th17 cells. Furthermore, miR-155
has been involved in inhibiting the protein suppressor of cytokine signaling 1 (SOCS1) in
activated CD4+ T cells (136) Mice lacking miR-155 (mir-155-/-) have reduced EAE
disease severity accompanied by less CNS inflammation and decreased Th1 and Th17
responses (136) In addition, in the current study, we also noted that cannabinoid
treatment led to down-regulation of miR-31, which targeted FoxP3. This is consistent
with previous findings that miR-31 targets Foxp3 and it is under expressed in human
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natural Tregs (137) Also, it has been shown that conditional deletion of miR-31 leads to
an increase in peripheral Tregs and reduced severity of EAE (138)
Studies from our laboratory have shown that THC and CBD when tested
individually can trigger apoptosis in immune cells as well as in some cancer cell lines
(94) (17, 139-141) However, roles of miRNA in the regulation of cannabinoid-mediated
apoptosis in immune cells are not clearly understood, especially with respect to MNCs
isolated from the brain during neuroinflammation. In the current study, we noted that
THC+CBD treatment led to significant increase in apoptosis in brain MNCs, which also
showed decrease in G0/G1 phase of cell cycle and increase in G2M phase. Our results
demonstrated that THC+CBD treatment caused downregulation of some miRNAs like
miR-122-5p and miR-21a-5p, which may target genes that regulate cell cycle arrest and
apoptosis such as Bcl2L11, CCNG1 and CDKN2A, which were found to be upregulated.
Moreover, treatment with THC+CBD led to upregulation of miRNAs such as miR-7065p. It has been reported that miR-706-5p affects the expression of cell division cycle
associated 4 gene, Cdca4, a gene that is important for cell cycle G1 phase progression
specifically through the E2F/retinoblastoma protein pathway (142) Also, miR-706-5p
downregulates the activity of Cacul1, which is a cell cycle associated protein capable of
promoting cell proliferation through the activation of CDK2 at the G1/S phase
transition(143) In addition, some of the miRNA may also target FoxP3 expression. For
example, our pathway analysis showed that miR-31 may regulate FoxP3 consistent with
previously published findings that this miR negatively regulates FoxP3 expression in
Tregs (137). Interestingly, we noted that THC+CBD treatment led to significant downregulation of miR-31 and an increase in FoxP3 expression in brain MNCs.
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While THC+CBD treatment led to alterations in many miRNAs, we further focused
our studies on Mir-21. We observed that Mir21-/- mice were more resistant to EAE when
compared to WT mice; these data suggested that miR-21 does play a critical role in EAE.
These data are consistent with previous studies showing that miR-21 deficiency leads to
increased resistance to EAE (144) Because our data also demonstrated that THC+CBD
treatment caused down-regulation of miR-21, these data together suggested that miR-21
may play a critical role in cannabinoid-mediated attenuation of EAE.

However, when

we treated Mir21-/- mice with THC+CBD, we found that these mice exhibited further
reduction in EAE thereby suggesting that additional miRNAs may also be involved in the
efficacy of cannabinoids to suppress EAE.
In conclusion, this combination therapy resulted in alleviation of the clinical
symptoms of EAE, a mouse model of human MS. Treatment of THC+CBD resulted in
reduction of the clinical signs of disease, reduction in pro-inflammatory cytokine
production, and decreased inflammatory infiltration of cells into the CNS, which prevents
the hallmark of disease progression, which is the demyelination of neuronal cells. Acting
in a neuroprotective manner, we observed that THC+CBD induced apoptosis and cell
cycle arrest (G2/M) in brain-infiltrating cells. From a mechanistic standpoint, we found
that this combination therapy leads to dysregulation of several miRNA, posttranscriptional modifiers of gene expression. We were able to correlate this miRNA
dysregulation to several features of cellular pathways, such as apoptosis and cell cycle
arrest. Specifically, in the current study we show decreased expression of miR-21
correlates with increased expression of the target Bcl2L11, a pro-apoptotic factor
belonging to the BCL-2 family of proteins.
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Figure 2.1 Combination of THC+CBD attenuates EAE by suppressing
neuroinflammation. EAE was induced in C57BL/6 mice using CFA+PTX+MOG, as
described in Methods. These mice were treated with cannabinoids and the mice were
studied for clinical signs of paralysis and neuroinflammation. (A) Experimental timeline.
EAE mice were treated daily with THC (10mg/kg), CBD (10mg/kg), or a combination of
THC+CBD (10mg/kg each) starting at 8-10 days after MOG immunization. (B) Controls
consisting of mice that received CFA+PTX only that received cannabinoids. (C&D)
Clinical scoring of EAE symptoms in mice treated with Veh, THC, CBD, or THC+CBD.
(E&F) EAE scoring in an extended experiment until day 27 in Veh vs THC+CBD treated
EAE mice. (G) Representative H&E images and LFB staining in spinal cord tissues to
detect cellular infiltration and demyelination, respectively. (H&I) EAE scoring in WT or
CB1-/-CB2-/- double knockout mice treated with either Veh or THC+CBD. (J)
Withdrawal latency time during the hot plate test to quantify analgesic sensitivity. Data
presented are mean +/- SEM. For (B-C & H), significance was determined by two-way
ANOVA with a Dunnett post hoc test. For (D & I), one-way ANOVA with a Dunnett
post hoc test was used. For (E) Mann-Whitney U test was performed excluding scoring
values before initiation of treatment. For (F), an unpaired two-tailed T-test was
performed. For (J), one-way ANOVA with a Sidak correction was used. ****p<0.0001,
***p<0.001, *p<0.05.
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Figure 2.2 T cell population and phenotypic changes of WT and CB1 -/-CB2 -/- EAE
mice treated with vehicle or THC+CBD. As shown in Figure 1, EAE was induced in
naïve mice then mice were treated with Veh or THC+CBD when symptoms appeared.
Inguinal lymph nodes and brain MNCs were collected at the peak of disease (Day 15 post
immunization). (A) IL-17A and IFNγ concentration in inguinal lymph node 24h culture
supernatant measured by ELISA. (B) Representative flow cytometry contour plots of
encephalitogenic T cells. (C) Quantification of total MNCs, CD3+ T cells, and
CD3+CD4+ Th cells per brain. Data presented are mean +/- SEM. ***p<0.001, *p<0.05
by unpaired two-tailed T test (A), or Kruskal-Wallis test (C).
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Figure 2.3 Differentially expressed miRNAs in brain-infiltrating CD4+ T cells upon
THC+CBD treatment in EAE mice. Total RNA was isolated and pooled from CD4+ T
cells obtained from the brains of EAE mice post-treated with vehicle (n = 5) or
THC+CBD (n = 5) on day 15. MicroRNA microarray expression levels of differentially
expressed miRNAs were generated. (A) The fold change distribution of all 1,908
miRNAs tested. (B) Proportional Venn diagram illustrating fold change of miRNAs that
were >1.5- fold dysregulated following treatment with THC+CBD in EAE mice. (C)
Heat map of the 157 dysregulated miRNAs. The color scale denotes those miRNAs that
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were upregulated (red) and downregulated (green). (D) Pathway analysis of miRs
mediating dysregulation in gene expression following THC+CBD treatment. (E-M)
Expression levels of selected upregulated and downregulated miRNAs were validated by
qRT-PCR using Snord96a as a small RNA endogenous control. Data presented are mean
+/- SEM. ***p<0.001, **p<0.01, *p<0.05 by unpaired two-tailed T test.
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Figure 2.4 Expression of miRNA target genes involved in Th cell polarization. As
described in Figures 2 and 3, CD4+ T cells or total MNCs were isolated from brains of
EAE mice on day 15 post immunization. For panels A-K, RNA was extracted from
CD4+ T cells and used for miR target gene validation. For panel L, total MNCs were
cultured for 24h and supernatants were collected for cytokine analysis. (A-K) qRT-PCR
validation of the target genes (A) Foxp3, (B) STAT5B, (C) IL-10, (D) GATA3, (E) IL-4
(F) STAT3, (G) IL-17A, (H) TBX21, (I) IFN-γ, (J) IL-6 and (K) IL-1β using GAPDH as
endogenous control. (L) IL-17A, IFN-γ, TNF-α, IL-6 IL-1β, IL-10 and TGF-β
concentration measured in MNC culture supernatants by ELISA. Data are expressed as
the mean ± S.E.M. and statistical significance is indicated as ***p<0.001, **p<0.01 by
unpaired two-tailed T test.
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Figure 2.5 THC+CBD treatment induces cell cycle arrest / apoptosis in brain MNCs.
As shown in Figure 1, EAE was induced in naïve mice and treatment with Veh or
THC+CBD was initiated at the onset of symptoms. CD4+ T cells and total MNCs were
isolated from the brains of mice on day 15 post immunization for gene and cell cycle
analysis. (A-D) qRT-PCR validation of miR target genes involved in cell cycle/apoptosis.
(E) Representative flow cytometry histograms of PI staining in brain MNCs using
ModFit software. (F) Cell cycle phase quantification. (G) Representative flow cytometry
pseudocolor plots of brain MNCs in early apoptosis (AnnexinV+PI-) or late apoptosis
(AnnexinV+PI+). (H) Quantification of brain MNCs in early or late apoptosis. Data
represented are mean +/- SEM. ***p<0.001, **p<0.01 by unpaired two-tailed T test (AD), or two-way ANOVA with a Tukey post hoc test (F & H).
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Figure 2.6 Role of miR-21a-5p downregulation on THC+CBD-mediated
amelioration of EAE. For (A-D), miR-21a-5p transfection assays were performed in
CD4+ T cells purified from naïve WT C57BL6 mice. Cells were cultured for 24h and
transfected with miR-21a-5p mimic, inhibitor, or mock (transfection reagent only).
For (E-F) EAE was induced in WT and Mir21-/- mice as described in Methods then
treated with Veh or THC+CBD upon development of EAE symptoms. (A-D) qRTPCR validation for miR-21 and the target genes. (E) Agarose gel electrophoresis of
genotyping for the parents and the first generation of Mir21-/- mice (miR-21 KO). (F)
EAE scoring in WT and Mir21-/- mice. (G) Quantification of the clinical scores. (H)
Representative flow cytometry histograms of brain MNCs stained with PI study cell
cycle analysis. (I) Quantification of cell cycle phases. Data are expressed as the mean
± S.E.M. and statistical significance is indicated as ***p<0.001, **p<0.01, *p<0.05.
For (F), statistical significance is vs. WT EAE+Veh. Significance was determined by
one- or two-way ANOVA with Tukey post hoc corrections.
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Table 2.1 3’UTR alignments and scores of miRNAs and their target genes
CCNG1
3' guuugugguaacagUGUGAGGu 5' mmu-miR-122
|||||||
1796:5' uuaggcuugauaaaACACUCCa 3' Ccng1
3' uuggguacCUUAAG---UCAAGAGu 5' mmu-miR-146a
||| || |||||||
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921:5' agaacgaaGAACUCCCAAGUUCUCu 3' Ccng1
3' cgcCUUGAAUCGGUGACACUu 5' mmu-miR-27a
||| | | |||||||
1306:5' uguGAAAUAA--AACUGUGAa 3' Ccng1
3' guguuugguaauacACGACGAu 5' mmu-miR-15a
|||||||
1682:5' aaauuugucagaacUGCUGCUu 3' Ccng1
3' guGACCAUGUUCCCAACCCUCu 5' mmu-miR-150
||| | | | | |||||||
1226:5' ucCUGAUUCUAAGCUUGGGAGa 3' Ccng1
CDKN1b

mirSVR
score:
1.0549
PhastCons 0.5536
score:
mirSVR
score:
0.1505
PhastCons 0.4986
score:
mirSVR
score:
1.0267
PhastCons 0.5944
score:
mirSVR
score:
0.4111
PhastCons 0.5536
score:
mirSVR
score:
0.2496
PhastCons 0.5917
score:

3' aguUGUAGUCAGACUAUUCGAu 5' mmu-miR-21
|:| :|||:| |||||||
1093:5' cuuAUAAUAGUUU-AUAAGCUc 3' Cdkn1b
3' gugUUUA-AGC-CUA-GAUGUCCCAu 5' mmu-miR-10a
:||| | | ||| |||||||
1236:5' aagGAAUAUAGAGAUGGCACAGGGUu 3' Cdkn1b
3' gugACCAUGUU-CCCAACCCUCu 5' mmu-miR-150
| || || || ||||||
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1376:5' aagUUGUCGAAUUGGAUGGGAGu 3' Cdkn1b
3' ugGGGAUAGUGUUAAUCGUAAUu 5' mmu-miR-155
:::|| |:: ||:||||||
1811:5' caUUUUAGAAUGUUUGGCAUUAu 3' Cdkn1b
3' gucGAUACGGUCGUAGAACGGa 5' mmu-miR-31
| | || || | ||||||
232:5' uucCCAAGCAAG-AACUUGCCa 3' Cdkn1b
Bcl2l11
3' gugagucguGGUCCUAUAACAa 5' mmu-miR-338-5p
| || :||||||
803:5' ggguaucuuCAAGUGUAUUGUg 3' Bcl2l11

mirSVR
score:
0.5432
PhastCons 0.537
score:
mirSVR
score:
0.1534
PhastCons 0.537
score:
mirSVR
score:
0.0062
PhastCons 0.5328
score:
mirSVR
score:
0.0055
PhastCons 0.5372
score:
mirSVR
score:
0.0062
PhastCons 0.5482
score:

mirSVR
score:
0.0008
PhastCons 0.5603
score:

3' aguUGUAGUCAGACUAUUCGAu 5' mmu-miR-21
|:||:| || |||||||
1814:5' uguAUAUUA-CCU-AUAAGCUu 3' Bcl2l11
3' guguuuaagccuagauGUCCCAu 5' mmu-miR-10a
||||||
785:5' augcgcagcuucagccCAGGGUa 3' Bcl2l11
IL10
3' gugaccauguucccaACCCUCu 5' mmu-miR-150
||||||
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290:5' gauuauauuauaugaUGGGAGg 3' Il10
3' uuGGGUACCUUAAGUCAAGAgu 5' mmu-miR-146a
| | | |||| ||||||
578:5' acCACCUAAAAUU-AGUUCUaa 3' Il10
3' aguuguagucagacuAUUCGAu 5' mmu-miR-21
||||||
233:5' uuuuuaaccuguguuUAAGCUg 3' Il10
3' uccGUAUCCUACUGUUUCCCUu 5' mmu-miR-204
:|||| || :|||||||
270:5' cuuUAUAGUAU-UUAAAGGGAg 3' Il10

mirSVR
score:
0.1597
PhastCons 0.546
score:
mirSVR
score:
0.0017
PhastCons 0.5603
score:

mirSVR
score:
0.0295
PhastCons 0.6418
score:
mirSVR
-0.586
score:
PhastCons 0.7581
score:
mirSVR
-0.155
score:
PhastCons 0.6617
score:
mirSVR
score:
1.2036
PhastCons 0.6418
score:

3' uuGGGUACCUUAAGUCAAGAgu 5' mmu-miR-146a
| | | |||| ||||||
578:5' acCACCUAAAAUU-AGUUCUaa 3' Il10
3' cgccuUGAAUCG--GUGACACUu 5' mmu-miR-27a
||| ||| | ||||||

mirSVR
-0.586
score:
PhastCons 0.7581
score:
mirSVR
score:
0.0968
PhastCons 0.6709
score:

165:5' uauucACUGAGCUUCUCUGUGAa 3' Il10
Foxp3
3' uccguaUCCUACUGUUUC-CCUu 5' mmu-miR-204
|| | || |||| |||
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896:5' gaucccAGCAGGAGAAAGCGGAu 3' Foxp3
3' gucgauacggucguaGAACGGa 5' mmu-miR-31
||||||
695:5' guaccccacgucucaCUUGCCa 3' Foxp3
3' guGUUUGGUAAUACAC-GACGAu 5' mmu-miR-15a
|:::| || ||||| |||||
97:5' acCGGGCGAUGAUGUGCCUGCUa 3' Foxp3
3' guuugugguaacaguGUGAGGu 5' mmu-miR-122
||||||

mirSVR
-0.194
score:
PhastCons 0.5948
score:
mirSVR
--score:
0.6807
PhastCons 0.7094
score:
mirSVR
score:
0.1344
PhastCons 0.5291
score:
mirSVR
score:
0.0057
PhastCons 0.5172
score:

1243:5' guauguccuucccucCACUCCa 3' Foxp3
IL17a
3' aaaaaacucuguccCAAAGAGa 5' mmu-miR-706
|||||||

mirSVR score:
PhastCons
score:

23:5' uaagaaacccccacGUUUCUCa 3' Il17a
TNF
5' ...CCCAGUGUGGGAAGCUGUCUUCA… (Position 529-535) Targetscan context score :-0.17
|||||||
3'
AAAAAAAAGGACUACAGAAGU mmu-miR-7116-5p
Targetscan context++ score percentile: 86
IL6
5' ...UUAUAAUGUUUAGAC-UGUCUUCA… (Position 390-397) Targetscan context score :-0.57
||| |||||||
3'
AAAAAAAAGGACUACAGAAGU mmu-miR-7116-5p
Targetscan context++ score percentile: 99

-0.6735
0.4105
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Table 2.2 miRNAs with their seed sequences and fold changes
MicroRNA
Identification

MicroRNA Sequence 5`-3`

Seed
Sequence

Fold
Change

miR-7116-5p

UGAAGACAUCAGGAAAAAAAA

GAAGACA

6.8

miR-706

AGAGAAACCCUGUCUCAAAAAA

GAGAAAC

10.4

miR-122-5p

UGGAGUGUGACAAUGGUGUUUG

GGAGUGU

-25.8

miR-21a-5p

UAGCUUAUCAGACUGAUGUUGA

AGCUUAU

-2.4

miR-155-5p

UUAAUGCUAAUUGUGAUAGGGGU

UAAUGCU

-2.5

miR-338-5p

AACAAUAUCCUGGUGCUGAGUG

ACAAUAU

-1.8

miR-146a-5p

UGAGAACUGAAUUCCAUGGGUU

GAGAACU

-1.7

miR-31-5p

AGGCAAGAUGCUGGCAUAGCUG

GGCAAGA

-4.7

miR-27-5p

AGGGCUUAGCUGCUUGUGAGCA

GGGCUUA

-1.8

miR-204-5p

UUCCCUUUGUCAUCCUAUGCCU

UCCCUUU

-6.5
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Table 2.3 mRNA quantitative RT-PCR primer sequences
Genes
Il10
Tgfβ
Il4
Gata3
Il17a
Ifng
Tbx21
Il6
TNF-α
Foxp3
SOCS1
Bcl2L11
CCNG1
CDKN2B
Cacul1
Cdca4
GAPDH

Primers Sequence (5′–3′)
Forward: CCCATTCCTCGTCACGATCTC
Reverse: TCCCATTCCTCGTCACGATCTC
Forward: ATGTCACGGTTAGGGGCTC
Reverse: GGCTTGCATACTGTGCTGTATAG
Forward: GGTCTCAACCCCCAGCTAGT
Reverse: GCCGATGATCTCTCTCAAGTGAT
Forward: CTCGGCCATTCGTACATGGAA
Reverse: GGATACCTCTGCACCGTAGC
Forward: TTTAACTCCCTTGGCGCAAAA
Reverse: CTTTCCCTCCGCATTGACAC
Forward: TCCTCGCCAGACTCGTTTTC
Reverse: GTCTTGGGTCATTGCTGGAAG
Forward: AGCAAGGACGGCGAATGTT
Reverse: GGGTGGACATATAAGCGGTTC
Forward: CCAAGAGGTGAGTGCTTCCC
Reverse: CTGTTGTTCAGACTCTCTCCCT
Forward: GGAACACGTCGTGGGATAATG
Reverse: GGCAGACTTTGGATGCTTCTT
Forward: CCCATCCCCAGGAGTCTTG
Reverse: ACCATGACTAGGGGCACTGTA
Forward: CTGCGGCTTCTATTGGGGAC
Reverse: AAAAGGCAGTCGAAGGTCTCG
Forward: GACAGAACCGCAAGGTAATCC
Reverse: ACTTGTCACAACTCATGGGTG
Forward: ACAACTGACTCTCAGAAACTGC
Reverse: CATTATCATGGGCCGACTCAAT
Forward: CCCTGCCACCCTTACCAGA
Reverse: CAGATACCTCGCAATGTCACG
Forward: AACACCTCCACCTCCAAGTT
Reverse: AGACTCGCTCTAAGTGGCTG
Forward: GTAGAGGGTTTTGGCACTGTC
Reverse: TGGGCTCCACTAGCATGTGA
Forward: TGGATTTGGACGCATTGGTC
Reverse: TTTGCACTGGTACGTGTTGAT
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CHAPTER 3
COMBINATION OF CANNABINOIDS, ∆9TETRAHYDROCANNABINOL (THC) AND CANNABIDIOL (CBD),
MITIGATES EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS (EAE) BY DIMINISHING THE GUT
MUCINS DEGRADER BACTERIA
3.1 ABSTRACT
Multiple Sclerosis (MS) is one of the most common autoimmune diseases that affects
the central nervous system (CNS). Currently there is no cure for patients suffering from
MS, and most treatments involve the use of immunosuppressive drugs that can have
adverse side effects or increased toxicity. Cannabis, traditionally known as marijuana, is
a product of the Cannabis sativa, an annual herbaceous plant, and for several centuries,
marijuana has been used as an alternative medicine in many cultures. Cannabis sativa has
over 421 chemical compounds, including about 80 terpenophenol compounds named
phytocannabinoids, which includes both delta-9-tetrahydrocannabinol (THC) and
cannabidiol (CBD). In the currently study, we show a combination therapy of THC and
CBD

(THC+CBD)

results

in

amelioration

of

experimental

autoimmune

encephalomyelitis (EAE), an animal model of MS, by reducing hind limb paralysis,
decreasing immune cellular infiltration into the brain, and preventing the presence of
inflammatory biomarkers. We performed 16S rRNA sequencing on bacterial DNAs
extracted from the experimental groups to investigate the gut microbiome compositions
after using a combination of THC and CBD after EAE induction. Interestingly, we found
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that EAE mice showed a high abundance of mucin degrading bacterial species, such as
Akkermansia muciniphila (A.muc), which was significantly reduced after THC+CBD
treatment. Fecal Material Transfer (FMT) experiments confirmed that THC+CBDmediated changes in the microbiome helped attenuate EAE clinical scores. Collectively,
our data suggests that THC+CBD can ameliorate disease by preventing EAE-associated
microbial dysbiosis which is characterized by an accumulation of mucin-degrading
bacteria such as A.muc.
3.2 INTRODUCTION
Multiple sclerosis (MS) is a chronic neuroinflammatory and demyelinating
autoimmune disorder of the central nervous system (CNS) mainly affecting young adults
worldwide and it is more common in women than men (145). The pathogenesis of this
disease includes development lead to demyelination. Although the complete etiology and
the pathogenesis of MS remains unclear, there is evidence that increased migration of
autoreactive lymphocytes across the blood-brain barrier (BBB) may be responsible for
axonal demyelination of neurons, which results in axonal injury, oligodendrocyte loss,
neuronal damage, and glial plaques (99). Experimental autoimmune encephalomyelitis
(EAE), an animal model of MS, is often used to study disease development and is
characterized by neurological dysfunction and demyelination closely mimicking
conditions in the human MS patient population (146-148). Most current treatments of
MS, such as interferon (IFN)-β, fingolimod, and glatiramer acetate act by regulating the
immune response (99, 149, 150), however these drugs are only partially effective in many
cases (20-30% successful in MS patients) and can have negative side-effects and
increased toxicity (151, 152). Since current treatments present many challenges to the
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patient population, new treatments are needed to improve the outcomes of patients who
are affected by MS.
Cannabis is a product of Cannabis sativa, an annual herbaceous plant, and for
several centuries this plant product has been used as an alternative medicine in many
countries (153). Cannabis sativa produces over 421 chemical compounds, including
about 80 terpenophenolic compounds named phytocannabinoids, which include both
THC and CBD (14). Research has shown cannabinoids are effective treatment options
against neurodegenerative diseases, including MS, because these plant products can
reduce disease-associated effects such as oligodendrocyte death and axonal damage (15,
154). In addition, THC+CBD combination therapy has been shown to effectively reduce
MS-associated tremors and spasticity, leading to ongoing human clinical trials (155-158).
Cannabinoids have also been shown to exert potent anti-inflammatory activities,
particularly through regulating immune cells involved in the innate and adaptive immune
response (15-17, 22, 159). More recent reports are exploring the role cannabinoids have
in regulating the gut microbiome, a major player in overall human host health and disease
(160-163).
The microbiome, consisting of a large population of commensal microbes, plays
such an important role in the health of the host it has been referred to as the “forgotten
organ” (164). Studies of MS patients and the EAE mouse model of MS have shown the
gut microbiome plays a significant role in disease both progression and severity (46, 165,
166). For example, it was found that germ-free mice developed a less severe EAE disease
with a reduction in pro-inflammatory IFN-γ and IL-17A T cell responses accompanied
with increase production of anti-inflammatory regulatory T cell (Tregs) (167). A more

49

recent study has shown that unaltered commensal bacteria can trigger a spontaneous form
of EAE after exposure to myelin oligodendrocytes glycoprotein (MOG) (168).
Interestingly, studies also found that the microbiome influences the development of the
BBB, as germ-free mice had disrupted formation of this important barrier protecting the
host CNS (169). Among the factors related to the microbiome which influence the host
immune system response, short chain fatty acids (SCFAs) are some of the most
significant functioning metabolites synthesized by the gut microbiome. SCFAs were
found to be critical modulators in the gastrointestinal tract capable of regulating the proinflammatory Th1/Th17 and anti-inflammatory Treg responses during autoimmune
neuroinflammation (170).
In the current study, we investigated the use of combination cannabinoid
treatment (THC+CBD) during EAE to determine how this treatment effects the gut
microbiome and whether these alterations influenced THC+CBD-mediated protective
effects. The results showed THC+CBD treatment of EAE results in reduction in disease
severity and alterations in the pro-inflammatory immune response. 16S rRNA sequencing
of colon contents revealed THC+CBD treatment altered the gut microbiome during EAE,
particularly by reducing the abundance of Akkermansia muciniphila (A.muc) which was
increased during the disease state. In addition to the alterations in the microbial
phylogenetic profile, THC+CBD treatment during EAE resulted in changes in the gut
metabolome, specifically leading to increases in SCFAs such as anti-inflammatory
butyrate. Lastly, fecal transfer experiments revealed that the protective effects of
THC+CBD during EAE was at least partly due to the alterations of the microbiome
during treatment with these combined cannabinoids.
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3.3 MATERIAL AND METHODS
Mice
6-8-week-old female C57BL/6 mice were purchased from the Jackson
laboratories (Bar Harbor, ME). Mice were housed in the Animal Resource Facility (ARF)
at the University of South Carolina, School of Medicine. All animal experiments were
performed in accordance with National Institutes of Health (NIH) guidelines under
protocols approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of South Carolina.
Reagents
The following reagents were used during the experiments and purchased as
follows: THC and CBD were from Cayman Chemical (Ann Arbor, MI); red blood cell
(RBC) lysis buffer and β-mercaptoethanol were from Sigma-Aldrich (St. Louis, MO);
percoll was purchased from GE Healthcare Life Sciences (Pittsburgh, PA); RPMI
1640, l-glutamine, HEPES, phosphate-buffered saline, and fetal bovine serum (FBS)
were from VWR (West Chester, PA); myelin oligodendrocyte glycoprotein (MOG35-55)
peptide

and

H-MEVGWYRSPFSRVVHLYRNGK-OH

were

from

PolyPeptide

Laboratories (San Diego, CA); Mycobacterium tuberculosis (strain H37Ra) and complete
Freund’s adjuvant were purchased from Difco (Detroit, MI); pertussis toxin was
purchased from List Biological Laboratories (Campbell, CA); Neural Tissue Dissociation
Kit (P) was purchased from Miltenyi Biotech Inc. (Auburn, CA); QIAamp DNA Stool
mini kit was purchased from Qiagen (Germantown, MD); Illumina MiSeq reagents were
purchased from Illumina, Inc. (San Diego, CA) except The Agencourt AMPure XP
system beads were purchased from Beckman Coulter Life Science (Indianapolis, IN);

51

Lipopolysaccharide (LPS) ELISA Kit (Sandwich ELISA) was purchased from LifeSpan
Biosciences, Inc. (Seattle, WA. USA). Besides, the following mouse-specific ELISA kits
were purchased from BioLegend (San Diego, CA): IL-10, IL-17A, IFN-, and TGF-.
EAE induction and treatment with THC+CBD
To investigate the effect of the THC+CBD combination, EAE was induced as
described previously (104, 105). Briefly, mice were given a subcutaneous injection with
100 μl of 150 μg MOG35-55 peptide emulsified in complete Freund’s adjuvant
containing 8 mg/ml killed Mycobacterium tuberculosis (strain H37Ra), followed by an
intraperitoneal injection (i.p.) of 200 ng of pertussis toxin on day 0. These injections were
repeated with 400 ng pertussis toxin on day 2. For treatment, EAE mice were randomized
and treated with an i.p. injection of 10 mg/kg THC+CBD or vehicle (2%
dimethylsulfoxide, DMSO; 20% ethanol diluted in PBS) on day 10 after the induction of
EAE, and this treatment regimen continued once daily until the end of the experiment.
Animals were monitored, and clinical scores were observed and evaluated daily.
EAE clinical scoring
The measured parameters for clinical EAE scores were recorded as follow: 0 =
normal; 1 = partial loss of tail tonicity/inability to curl the distal end of the tail; 2 = tail
atony/ moderately clumsy/impaired righting; 3 = hind limbs weakness/partial paralysis; 4
= complete hind limp paralysis/fore limb weakness; 5 = tetraplegia/moribund (106). The
mean score was calculated for each group every day. Proper care of paralytic animals
unable to access food and water was ensured by providing supplementary DietGel Boost
and Hydrogel from Daily H2O (Portland, ME) on a daily basis. Death was not used as an
index for clinical scores, and any mice that were moribund were immediately euthanized
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with an overdose anesthetic isoflurane (%5), a method approved by the American
Association for Laboratory Animal Science and university IACUC.
Histopathological analysis
For histopathological evaluation, brain tissues from experimental mice were
isolated at day 15 after EAE induction during the peak of disease. Prior to brain isolation,
euthanized mice were perfused with 10 mL heparinized PBS to flush out vascular
circulating cells. Isolated brain tissues obtained after perfusion were immersed in 4%
paraformaldehyde (PFA) overnight prior to embedding in paraffin. Microtome sections
(7 μm) were obtained, and tissue sections were stained with Hematoxylin and Eosin
(H&E) to evaluate damage and cellular infiltration into the CNS.
Analysis of cytokine production
Pro-inflammatory (IFNγ and IL17A) and anti-inflammatory (IL-10 and
transforming growth factor-, TGF-) cytokines were evaluated in the serum and ex vivo
splenocyte supernatants from experimental groups using ELISA kits as previously
described (104). For serum, blood was collected on day 15 and serum was separated and
stored at -80°C until analysis. For evaluation of the peripheral response in the spleen
during EAE, spleens from experimental mice were excised at the end of the experiment
and processed into a cell single suspension. Isolated splenocytes were seeded (1x106
cells/ml) cultured for 24 hours at 37°C and 5% CO2 overnight in complete RPMI 1640
media supplemented with 10% fetal bovine serum, 10 mM l-glutamine, 10 mM HEPES,
50 μM β-mercaptoethanol, and 100 μg/ml penicillin/streptomycin. After 24 hours, cell
culture supernatants were cultured and stored at -80°C until further analysis.
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Flow cytometry analysis for myeloid-derived suppressor cells (MDSCs)
To determine peripheral MDSC induction, spleens were excised prior to perfusion
in experimental mice. Whole splenocyte tissues were homogenized into a single cell
suspension and subjected to red blood cell (RBS) lysis. Cells suspensions from
experimental groups were tagged with fluorescently-labeled monoclonal antibodies
(mAbs) purchased from Biolegend. Specifically, PE-labeled Gr-1 and AlexaFluro700labeled CD11b were used to identify MDSC populations in the spleen. Antibody-tagged
samples were run a BD FACs Celesta flow cytometer and analyzed using FlowJo
software from BD Biosciences (San Jose, CA).
Bacterial phylogenetic and metabolomic profiling by 16S rRNA analysis
16S rRNA sequencing using the Illumina MiSeq platform and analysis with
Nephele were performed as previously described (171). Briefly, cecal flushes were
collected from Naïve, EAE-VEH and EAE-(THC+CBD) mice under antiseptic
conditions, and collected samples were kept frozen at - 80 °C until DNA extraction.
Isolation of DNA from stool was performed using the QIAamp DNA Stool Mini Kit from
Qiagen as per the instructions from the manufacturer. 200 mg of cecal contents was
collected per experimental mouse. Sequencing was performed on the Illumina MiSeq
platform to generate reads, and all further downstream analysis was performed using the
Nephele platform from the National Institute of Allergy and Infectious Diseases (NIAID)
Office of Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, MD
(172). To analyze phylogenetic and possible metabolomic alterations within samples,
Nephele-based analysis using the Phylogenetic Investigation of Communities by
Reconstruction of Unobserved States (PiCRUSt) option was used which requires a closed
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reference against the Greengenes database (Greengene_99) at taxa levels 2 and 3
(Phylum and Class) for KEGG annotations. In order to determine significantly altered
bacteria and processes within the samples, linear discrimination analysis of effect size
(LefSE) was performed operational taxonomic unit (OTU) tables generated from Nephele
(173). To validate A.muc (F 5GACTAGAGTAATGGAGGGGGAA 3 R
5GTATCTAATCCCTTTCGCTCCC 3) expression, PCR was performed using Qiagen
miScript cDNA synthesis kit and Biorad SSO advanced SYBR Green PCR reagents for
analysis on a CFX96 qPCR system. Fold change of A.muc was determined using the
delta-delta-CT

method

expressed

relatively

to

a

Eubacteria

(Forward:

5ACTCCTACGGGAGGCAGCAGT; 3 Reverse: 5ATTACCGCGGCTGCTGGC 3)
control.
Quantification of SCFAs
Quantification of SCFAs was performed as previously described (166, 171).
Briefly, 100mg of cecal contents was weighted and suspended in dIH2O to a final
concentration of 250 mg/mL. Samples were vortexed until completely homogenized, then
acidified with 1:4 volumes of 25% metaphosphoric acid. Acidified samples were
vortexed and placed on ice for 30 min. Cold acidified samples were centrifuged at
12,000xg for 15 minutes at 4°C. Supernatants were filtered over ultra-free MC columns
(0.22 um GVDurapore, UFC30GV0S, ThermoFisher Scientific) and centrifuge at
12,000xg for 4 minutes at 4°C. Samples were stored until later downstream quantification
at -80°C. To quantify SCFAs and determine their concentrations within experimental
samples, standards were prepared as shown in Table 1. Ethylbutyric acid (0.10 mM) was
added as an internal standard (IS) for all samples and standards tubes. The acidified
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samples were thawed and 100L was transferred to a new microfuge tube, along with
100L of the standards. For the IS-blank, 100L ddH2O was transferred to a new
microcentrifuge tube. Then, 60L of 0.1mM IS was added to each sample, standard, and
IS-blank for a final volume of 160 L. Two sets of glass GC vials (Supelco 29056-U)
were labeled for each sample, standard, and IS-blank.

Approximately 400L of

methyl tert-butyl ether (MTBE) was added to one set of glass vials using a 2mL glass
serological pipette. Samples, standards, and IS-blank from the tubes that had final volume
of 160L(100L ddH2O+60L of 0.1mM IS) were added into the glass vials containing
MTBE. Samples were vortexed ~5-10 seconds, then spun down at 1.300 rpm for 5
minutes at room temperature. Lastly, 100L of the top organic layer from the samples
was placed into the other set of glass vials for analysis. Samples were stored at -20°C
until analyzed with the gas chromatography flame-ionized detection (GC-FID)
instrument (174).
Lipopolysaccharide (LPS) Detection in brain lysates
Brain tissues were collected from naïve, EAE-VEH and EAE-(THC+CBD),
rinsed with 1X PBS, and minced into a single cell suspension. Cells were collected and
pelleted by centrifugation, and the supernatant was removed. Cells were washed 3 times
with 1X cold-PBS and suspended in 1X PBS to be lysed by freezing the cells at -20°C
and allowing to thaw at room temperature 3 times. Cells were centrifuged at 1500×g for
10 minutes at 4°C to remove cellular debris. The collected cell supernatants were
analyzed for detection of LPS by using a LPS ELISA Kit (Sandwich ELISA) for
LifeSpan Biosciences, Inc. (Seattle, WA) according to the manufacturer’s instructions.
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Fecal microbial transplantation (FMT)
In order to perform FMT experiments, the EAE model was induced as described
above. Cecal flushes from experimental groups, Naïve, EAE-VEH, and EAE(THC+CBD), were harvested aseptically at the peak of the disease (day 15) using an
anaerobic chamber were suspended in sterile PBS containing 30% glycerol for storage at
-80C until used. To prepare mice for FMTs, 6-week-old C57Bl/6J mice we administered
antibiotics (streptomycin 1g/L and ampicillin 1g/L, referred to as “Abx”) by oral gavage
(100μL) daily for 4 weeks. Abx-treated mice were kept in autoclaved cages with
autoclaved water and chow. To ensure depletion of the microbiome, PCR validation
(DNA

collected

from

stool)

using

a

primer

for

Eubacteria

(Forward:

5ACTCCTACGGGAGGCAGCAGT; 3 Reverse: 5ATTACCGCGGCTGCTGGC 3)
and bacterial culture plates were performed. EAE was induced in mice treated with Abx
for 4 weeks and after symptoms started, mice were randomized into 4 groups: FMT
EAE+Control

(PBS

only),

FMT

EAE+Naive,

FMT

EAE+VEH,

FMT

EAE+(THC+CBD). We performed daily FMTs (50mg) by oral gavage starting at day 10
until the end of the experiment (day 18).
Statistics
We performed our statistical analysis using GraphPad Prism 6 (GraphPad Inc, La
Jolla, CA). The data shown in this study represents at least three independent experiments
unless otherwise stated. Average values ± standard error mean (SEM) are shown for
experiments to determine to significance. The statistical differences between two
experimental groups were calculated using ANOVA and student t test. For comparisons
of three or more groups, one-way ANOVA and Tukey’s multiple comparisons posthoc
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test were performed. EAE clinical scores over a period of time were evaluated using
groups of at least five mice and significance was determined using two-way ANOVA and
Tukey’s multiple comparisons test in order to determine significance during each
individual time point (e.g. days). A P value <0.05 was considered significant for all
experiments.
3.4 RESULTS
Combination THC+CBD treatment reduces EAE disease and promotes antiinflammatory response
In order to determine the effectiveness of THC+CBD treatment in the EAE
model, disease induction and treatment were performed as outlined in Figure 1A, initially
comparing the following groups: EAE mice treated with vehicle (EAE-VEH) and EAE
mice treated with cannabinoid combination (EAE-(THC+CBD)). Clinical EAE scores
showed EAE-(THC+CBD) had reduced disease severity when compared to EAE-VEH
disease controls (Figure 1B). Histological results from the brains taken at day 15 of the
experimental model revealed that as expected, when compared to naïve wild-type (WT)
mice, EAE-VEH mice had high number of infiltrating cells and signs of tissue damage,
however, EAE-(THC+CBD) brain tissues showed similar naïve group morphology
(Figure 1C). Serum samples also showed EAE-(THC+CBD) mice had a decrease in the
pro-inflammatory cytokines levels for IL-17A (Figure 1D) and IFN- (Figure 1E) when
compared to the disease controls. However, EAE-(THC+CBD) serum had increases in
the levels of anti-inflammatory cytokines TGF- (Figure 1F) and IL-10 (Figure 1G)
compared to EAE-VEH groups. In the periphery, splenic levels of pro-inflammatory
cytokines IL-17A (Figure 1H) and IFN- (Figure 1I) were also reduced with THC+CBD
treatment, and this correlated with an increase in anti-inflammatory myeloid-derived
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suppressor cells (MDSCs) when compared to disease controls. Collectively, this data
showed that THC+CBD treatment was able to reduce EAE disease severity and promote
and anti-inflammatory response.
Combination THC+CBD treatment alters the gut microbiome during EAE
induction
16S rRNA gene sequencing was performed on cecal flushes from the following
groups: Naïve, EAE-VEH, and EAE-(THC+CBD). The Illumina MiSeq platform using
primers targeting the V3 and V4 variable regions was used. Sequences were translated by
using the 16S QIIME Paired-End pipeline implemented in Nephele platform (release 1.6
which uses QIIME 1.9.1) (175). OTUs were picked with QIIME’s unclust-based (176),
open-reference OTU picking protocol (177), and the taxonomic assignment was done
against Greengenes-99 reference sequence set at 99% similarity, as previously described
(178). Alpha diversity, as assessed using Chao1 rarefraction measure, showed that EAEinduced mice had slightly lower abundances of bacteria in the gut (Figure 2A). Beta
diversity, depicted in a 3D principle coordinate analysis (PCOA) plot, showed that three
experimental groups clustered together well within their own groups, suggesting there
was divergence in the gut microbiome population (Figure 2B). At the phylum level
(Figure 2C), there were notable differences in the taxa. EAE-induced mice had
significantly lower abundances of Bacteriodetes when compared to Naïve mice (Figure
2D), whereas EAE-treated with THC+CBD had higher levels of Firmicutes when
compared to the disease controls (Figure 2E). Both EAE groups had a significant drop in
Tenericutes when compared to the controls (Figure 2F), but had increased abundance of
Verrucomicrobia, although EAE-(THC+CBD) had reduced levels compared to EAEVEH (Figure 2G). Interestingly, Proteobacteria was significantly higher in EAE-VEH
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mice compared to controls, but the abundance of this phylum was reduced to normal
levels after treatment with THC+CBD (Figure 2H). Significant alterations in the gut
microbiome were observed throughout the various taxa levels from class to genus among
the experimental groups with an interesting consistent trend showing EAE-associated
increase in Verrucomicrobia sub-levels was decreased after THC+CBD treatment
(Supplementary Figures 1-4).
In order to ascertain the most significantly altered bacteria between naïve and
disease controls and identify any potential microbial biomarkers of disease, LefSE was
performed on the OTU output data (Figure 3A). When examining microbial disruption
between the Naïve and EAE-VEH groups, the bacterial species Akkermansia
muciniphilia (A.muc) within the Verrucomicrobiae class had the highest LDA score in
EAE-induced mice (Figure 3B). When considering the levels in treated groups, EAE(THC+CBD) mice had significantly reduced levels of this EAE-associated bacteria
(Figure 3C). The sequencing data was validated using primers specific for A.muc,
reinforcing the observation that THC+CBD treatment reduced the levels of this bacteria
that were significantly higher in EAE mice when compared to naïve controls (Figure 3D).
Treatment with THC+CBD during EAE alters gut bacterial metabolite production
In addition to the phylogenetic data from 16s rRNA sequencing, in silico
computational metabolomics was performed using the PICRUSt method. LefSE analysis
of the output data showed that when comparing disease controls (EAE-VEH) to EAE(THC+CBD) treated groups, several KEGG pathways had high LDA scores in the
disease state (Figure 4A). For example, LPS biosynthesis, a key component in gramnegative bacteria such as A.muc was found to be elevated in disease controls compared to
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naïve mice, but this was greatly reduced after treatment with THC+CBD (Figure 4B). In
order to corroborate this in silico data, brain lysates from experimental groups were
analyzed for detection of LPS levels. When comparing all the experimental groups,
lysates from the brains of EAE-VEH mice had significantly higher levels of LPS
compared to controls, however, EAE-(THC+CBD) mice reduced this level significantly
(Figure 4C). Production of known SCFAs was also evaluated from cecal flushes.
Compared to Naïve controls, EAE-induced mice (untreated or untreated) had higher
levels of acetic (Figure 4D) and propionic acids (Figure 4E), though only EAE(THC+CBD) mice appeared to have increased isobutyric acid (Figure 4F). In addition,
EAE-(THC+CBD) samples had significantly higher levels of butyric (Figure 4G),
isovaleric (Figure 4H), and valeric (Figure 4I) acids compared to naïve or disease
controls. Collectively, data showed EAE-(THC+CBD) mice had global increases in
SCFA production, in addition to altering other bacterial metabolomic pathways such as
LPS production.
FMT of THC+CDB-altered microbiome attenuates EAE disease severity
In order to determine if the alterations in the microbiome by THC+CBD treatment
mediated any protective effects against EAE induction, FMT experiments were
performed as described in Figure 5A. To deplete the microbiome, mice were treated with
Abx for 4 weeks, and confirmation of this depletion was confirmed with PCR (Figure
5B) and bacterial culturing (Figure 5C). For FMTs, EAE-induced mice were fed either
controls (FMT EAE Control), or fecal material from Naïve (FMT EAE-Naïve), disease
controls (FMT EAE-VEH), or disease mice treated with THC+CBD (FMT EAE(THC+CBD)). When assessing the clinical scores after EAE induction, all mice treated
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with Abx had reduced disease severity compared to normal EAE experiments (Figure
5D), more than likely due to the dependency of EAE induction on the microbiota.
However, FMT EAE-(THC+CBD) mice had significantly reduced scores compared to
the other groups. This data confirms that alterations in the microbiome by combination
THC+CBD leads to protection against EAE-induction, thus providing another interesting
mechanism by when cannabinoids are capable of protecting against inflammatory
diseases.
3.5 DISCUSSION
MS is a neurological autoimmune disease caused by a combination of genetic and
environmental exposures which has increased in incidence in the past several decades
suggesting a changes in environmental risk factors (179), and gut microbiota might be
one of these environmental factors (50). Our study demonstrated a mixture of
cannabinoids (THC and CBD) in EAE resulted in alleviation of the clinical symptoms. A
previous report from our lab also found that treatment with CBD alone was able to
attenuate EAE-induced disease (16). Such findings were observed even 20 years ago
when it was reported that a MS patient who smoked marijuana had decreased incident of
MS-associated ataxia and spasticity (180), and since then several reports have shown
cannabinoids are effective at lessening MS disease burden (181, 182). There is even a
oromucosal pharmaceutical cannabinoid spray (Sativex) available to reduce spasticity
and pain attributed to MS (183). In fact, there is a reported increase in use of cannabis by
MS patients in the United States (184). Such an increase in use is not surprising given the
evidence of benefits available from research.
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Several mechanisms have been attributed to the beneficial effects of cannabinoids
like THC and CBD, to include those that affect the immune system. In the current report,
treatment with THC+CBD resulted in reduction of pro-inflammatory cytokines
production and increase in anti-inflammatory cytokines production. In early reports,
Kozela et al found that CBD was found to suppress microglial activity and prevent T cell
proliferation associated with inducible EAE (185). The same research group later
reported that separately THC and CBD were able to suppress Th17 cells and
proinflammatory cytokines such as TNFα and IFNγ during EAE (19), consistent with our
combination treatment findings. In addition to suppressing the pro-inflammatory
phenotype, our lab has also shown that cannabinoids are able to increase abundance and
activity of anti-inflammatory immune cell phenotypes, such as Tregs and MDSCs, in
various inflammatory models of disease (16, 18, 22, 121, 159, 186). Therapeutic agents
that can reduce pro-inflammatory Th1/Th17 subsets and increase anti-inflammatory
Th2/Treg/MDSC subsets can potential help patients suffering from MS, reinforcing the
case that these cannabinoids are a good source of alternative therapy for the patient
population. Despite a continuing field of research in cannabinoids and MS, few have yet
to study another possible mechanism linked to the disease, which consists of examining
the effects occurring in the microbiome.
Current research has noted that MS is characterized by alterations in amount,
composition, and metabolomic profile of the microbiome (187). Of particularly note in
this study was during EAE induction and treatment significant changes were observed in
A. Muc which is reported to be involved in exacerbation of both the human MS patients
and animal models of MS, like EAE (187, 188). For example, it was found that increased
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A. Muc in MS patients was capable of increasing the severity of EAE when transplanted
into mice (189). In a study done by Jangi et al., researchers found that the genus
Akkermansia increased in patients with MS (50). In another study, researchers found that
untreated MS subjects showed increase of Akkermansia as well (190). The current report
suggests that cannabinoid treatment may be able to regulate A. Muc, which is certainly
possible given that blocking cannabinoid receptors lead to a significant increase in A.
Muc in an model of obesity (161). Interestingly, use of another natural product
(resveratrol) was found to regulate the endocannabinoid system to decrease A. Muc in
high-fat diet-induced non-alcoholic steatohepatitis (191).
Microbial dysbiosis in MS/EAE hosts characterized by increased gram-negative
bacteria, such as A.Muc, could be linked to increased LPS, which was observed in brain
lysates from EAE mice in the current study. Elevated LPS levels suggest a shift to
increased presence of gram negative bacterial endotoxin and a study has shown LPS
results in degeneration of myelin and results in white matter damage (192). This makes
sense as LPS is linked to a proinflammatory response in the host capable of activating
microglia, disrupting the BBB, and making Tregs act in a defective manner (193). In
addition, the current study shows THC+CBD treatment results in widespread increases in
SCFAs. SCFAs play a very important role in regulating the inflammatory response and
preventing autoimmune diseases such as MS by suppressing the production of Th17 cells
and promoting the production of Treg cells from CD4 naïve T cells (194). In fact, a
recent report showed that gut dysbiosis and lack of SCFAs were present in Chinese MS
patients (195). The results of all these aforementioned studies, combined with the results
in EAE treated with THC+CBD, provide an interesting therapeutic approach and target in
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the future treatment of MS patients, by way of altering the gut microbiome and
preventing MS-associated microbial dysbiosis.
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Figure 3.1 Combination THC+CBD treatment attenuates EAE disease severity
and promotes anti-inflammatory immune response. (A) Experimental design of
EAE experiments using combined treatment of THC+CBD (10mg/kg). (B) Clinical
scores, outlined in the Materials and Methods section, of EAE mice treated with
VEH (n = 10) or THC+CBD (n = 10). Significance was determined using two-way
ANOVA and Tukey’s multiple comparisons test to evaluate significance at each day.
Significant p values (*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001) are
indicated below respective days after EAE induction. (C) Representative images of
brain histopathology stained with H&E (10×) at day 15 from experimental groups:
Naïve, EAE+VEH, and EAE+THC; scale bars, 100 µM. (D-G) Serum was collected
at the peak of the disease (day 15) to determine levels of IL-17A (D), IFN-γ (E),
TGF-β (F), and IL-10 (G). (H-I) Supernatants from cultured splenocytes were
collected after 24hrs to analyze IL-17A (H) and IFN-γ (I) by ELISA. (J-K)
Representative flow cytometry plots (J) to determine MDSC (Gr-1+CD11b+)
percentages (K). Bar graph data are expressed as the mean ± SEM and statistical
significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001
when compared between EAE-VEH and EAE-(THC+CBD) unless otherwise stated.
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Figure 3.2 Combination THC+CBD treatment alters the gut microbiome during
EAE disease. (A-B) 16S rRNA sequencing from the cecal flushes was performed on
Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6) experimental mice and
data are representative of one experiment. Sequenced reads were analyzed using
Nephele to generate chao1 alpha diversity (A) and beta diversity PCOA (B) plots. (C)
Depicted stacked bar graphs of percent OTUs at the phylum level. (D-H) Individual
bar graphs are depicted for the following phylum level: Bacteriodetes (D), Firmicutes
(E), Tenericutes (F), Verrucomicrobia (G), and Proteobacteria (H). Bar graph data are
expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using
one-way ANOVA and Tukey’s multiple comparisons test
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Figure 3.3 LefSE analysis identifies A.Muc as a potential biomarker of EAE disease
which is reduced after THC+CBD treatment. (A-B) 16S rRNA sequencing from the
cecal flushes was performed on Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD)
(n=6) experimental mice and OTU data was subjected to LefSE analysis to generate
cladogram (A) and LDA scores (B) between Naïve and EAE-VEH groups. For LefSe
data, the alpha factorial Kruskal-Wallis test among classes was set to 0.05, and the
threshold on the logarithmic LDA score for discriminative features was set at3. (C) Bar
graph depicting the percent OTUs of A.Muc generated from 16S rRNA sequencing in
Naïve, EAE-VEH, and EAE-(THC+CBD) groups. (D) Bar graph depicting PCR
validation and fold change of A.Muc in Naïve (n=5), EAE-VEH (n=5), and EAE(THC+CBD) (n=5) groups. Bar graph data are expressed as the mean ± SEM and
statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P <
0.0001. Significance was determined using one-way ANOVA and Tukey’s multiple
comparisons test.
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Figure 3.4 Combination THC+CBD treatment alters the gut microbiome
metabolome during EAE disease. (A) LDA scores between EAE-VEH and EAE(THC+CBD) groups using PICRUSt-generated Level 3 (L3) KEGG pathways of 16S
rRNA sequencing data from Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6)
experimental mice. (B) Individual bar graph depicting percent OTUs attributed to LPS
biosynthesis from Naive (n=4), EAE-VEH (n=5), and EAE-(THC+CBD) (n=6)
experimental mice after PICRUSt analysis. (C) Concentration of LPS levels from
cultured brain lysates detected by ELISA for Naive (n=5), EAE-VEH (n=5), and EAE(THC+CBD) (n=5) samples. (D-I) Concentrations of SCFAs from cecal flushes of Naive
(n=5), EAE-VEH (n=5), and EAE-(THC+CBD) (n=5) samples. Bar graph data are
expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05, **P <
0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using one-way
ANOVA and Tukey’s multiple comparisons test.
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Figure 3.5 FMT of THC+CBD altered microbiome attenuates EAE severity. (A)
Experimental design of FMT EAE experiments where 4-week Abx-treated mice received
FMTs (50mg) from either Control PBS (n=3), Naïve (n=3), EAE-VEH (n=5), or EAE(THC+CBD) (n=5) mice. (B) PCR validation confirming Abx mice had depleted
microbiome. Depicted is the fold change of Eubacteria normalized to 18S compared
between WT(n=5) and WT+Abx (n=5). Bar graph data are expressed as the mean ± SEM
and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P < 0.001 and ****P
< 0.0001 (C) Representative feces cultured plates from WT (n=4) and WT+Abx (n=4)
mice to confirm depletion of microbiome. (D) Clinical scores, outlined in the Materials
and Methods section, of FMT EAE mice treated with Control PBS (n=3), Naïve (n=3),
EAE-VEH (n=5), or EAE-(THC+CBD) (n=5) fecal material. Significance was
determined using two-way ANOVA and Tukey’s multiple comparisons test to evaluate
significance at each day. Significant p values (*P < 0.05, **P < 0.01, ***P < 0.001 and
****P < 0.0001) are indicated below respective days after EAE induction.
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Figure 3.6 16S rRNA analysis of EAE treated with THC+CBD at the class level. (AB) Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA
analysis was performed as described in Figure 2 legend and Materials and Methods for
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A)
Depicted are stacked bar graphs for percent OTUs at the class level. (B) Significantly
altered bacteria at the class level depicted as bar graphs. Bar graph data are expressed as
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P <
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and
Tukey’s multiple comparisons test. Data are representative of one independent
experiment.
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Figure 3.7 16S rRNA analysis of EAE treated with THC+CBD at the order level. (AB). Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA
analysis was performed as described in Figure 2 legend and Materials and Methods for
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A)
Depicted are stacked bar graphs for percent OTUs at the order level. (B) Significantly
altered bacteria at the order level depicted as bar graphs. Bar graph data are expressed as
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P <
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and
Tukey’s multiple comparisons test. Data are representative of one independent
experiment.
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Figure 3.8 16S rRNA analysis of EAE treated with THC+CBD at the family level.
(A-B). Induction of EAE and treatment with THC+CBD, followed by Nephele 16S
rRNA analysis was performed as described in Figure 2 legend and Materials and
Methods for Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental
groups. (A) Depicted are stacked bar graphs for percent OTUs at the family level. (B)
Significantly altered bacteria at the family level depicted as bar graphs. Bar graph data
are expressed as the mean ± SEM and statistical significance is indicated as *P < 0.05,
**P < 0.01, ***P < 0.001 and ****P < 0.0001. Significance was determined using oneway ANOVA and Tukey’s multiple comparisons test. Data are representative of one
independent experiment.

73

Figure 3.9 16S rRNA analysis of EAE treated with THC+CBD at the genus level.
(A-B) Induction of EAE and treatment with THC+CBD, followed by Nephele 16S rRNA
analysis was performed as described in Figure 2 legend and Materials and Methods for
Naïve (n=4), EAE+VEH (n=5), and EAE+(THC+CBD) (n=6) experimental groups. (A)
Depicted are stacked bar graphs for percent OTUs at the genus level. (B) Significantly
altered bacteria at the genus level depicted as bar graphs. Bar graph data are expressed as
the mean ± SEM and statistical significance is indicated as *P < 0.05, **P < 0.01, ***P <
0.001 and ****P < 0.0001. Significance was determined using one-way ANOVA and
Tukey’s multiple comparisons test. Data are representative of one independent
experiment.
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Table 3.1 Source and concentration of SCFAs standards

Acid

Vendor (Cat. No.)

Concentration(mM)

L

Water(ddH2O)
Acetic
Propionic
n-Butyric
Isovaleric
Valeric
Isobutyric
Caproic
n-Heptanoic

Acros Organics (64-19-7)
Sigma (402907)
Sigma (B103500)
Sigma (129542)
Sigma (240370)
Sigma (58360)
MP Biomedicals (101242)
Sigma (75190)

400
400
400
200
200
100
50
50

422.3
11.5
14.9
18.3
11.0
10.9
4.6
3.0
3.5
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CHAPTER 4
AHR ACTIVATION BY TCDD (2,3,7,8-TETRACHLORODIBENZOP-DIOXIN) ATTENUATES PERTUSSIS TOXIN-INDUCED
INFLAMMATORY RESPONSES BY DIFFERENTIAL
REGULATION OF TREGS AND TH17 CELLS THROUGH
SPECIFIC TARGETING OF MICRORNA
4.1 ABSTRACT
TCDD

(2,3,7,8-Tetrachlorodibenzo-p-dioxin),

a

halogenated

aromatic

hydrocarbon, is an environmental contaminant and potent ligand for Aryl hydrocarbon
hydroxylase (AhR) ligand. Pertussis Toxin (PTX) is a virulence factor found in
Bordetella pertussis, a human respiratory pathogen that causes whooping cough. PTX
promotes colonization and disease promotion by triggering heightened inflammatory
response. In the current study, we investigated if AhR activation by TCDD can attenuate
PTX-mediated systemic inflammation. To this end, C57BL/6 mice were injected i.p.
with TCDD (25 g/kg body weight) or vehicle (VEH, corn oil) followed by an i.p.
injection of PTX (400 ng/mouse) Twenty-four hours later, mice were rechallenged with
the same dose of PTX and 3 days later, mice were euthanized for immunological studies.
PTX+VEH group has elevated levels of pro-inflammatory cytokines (IL-17A, IL-6, and
IFNγ) in serum and increased proportions of CD4+ Th1 and Th17 cells in spleens. In
contrast, PTX+TCDD group had significantly lower levels of these inflammatory
cytokines and decreased proportions of Th1 and Th17 cells but increased proportions of
Th2 and FoxP3+Tregs when compared to PTX+VEH group. PTX+TCDD treated mice
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also had elevated levels of IL-10, and TFG- , potent anti-inflammatory cytokines.
microRNAs (miRs) analysis of CD4+ T cells from the spleens of PTX+TCDD treated
mice revealed significant alterations in their expression and several of these miRs
targeted cytokines and signaling molecules involved in inflammation.

Specifically,

PTX+TCDD group had significantly enhanced expression of miR-3082-5p that targeted
IL-17, and decreased expression of miR-1224-5p, which targeted FoxP3. Transfection
studies with these miR mimics and inhibitors confirmed that this was indeed the
mechanism through which TCDD suppressed Th17 while inducing Tregs. Together, the
current study demonstrates that AhR activation by TCDD suppresses PTX-induced
inflammation through miR regulation that trigger reciprocal differentiation of Tregs and
Th17 cells. These studies also suggest that AhR activation may serve as a treatment
modality to suppress heightened inflammation induced during B. pertussis infection.
4.2 INTRODUCTION
TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), also known as dioxin, is one of the
polyhalogenated aromatic hydrocarbons compounds (196). TCDD is a potent agonist
with high binding affinity to aryl hydrocarbon receptor (AhR) because which it is
extensively used to study the impact of AhR activation on various physiological and
immune functions (197, 198). AhR is a basic helix-loop-helix/PAS transcription factor
localized in the cytoplasm. More recent studies have shown that AhR activation can
not only cause toxicity but also regulate the immune response, specifically the
regulation of T cell differentiation (199, 200) Activation of AhR by TCDD or other
ligands leads to translocation to the nucleus where it binds to its dimerization partner,
aryl hydrocarbon receptor nuclear translocator (ARNT). The AhR-ARNT complex
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initiates transcription of genes with promoters containing a dioxin-responsive element
(DRE) consensus sequence.(201, 202)

In addition to the well characterized ligand,

TCDD, a variety of other compounds including tryptophan derivatives, dietary flavonoids
and biphenyls have been shown to bind to AhR with varying affinities (203). While AhR
was initially discovered in the context of activation by environmental chemicals leading
to induction of xenobiotic metabolizing enzymes, and regulating the toxicity mediated by
such chemicals, more recent studies have shown that AhR activation plays diverse roles
in cellular functions, especially in the regulation of T cell differentiation (204).
Pertussis Toxin (PTX) is one of the most important virulence associated factors of
Bordetella pertussis, the gram-negative bacterium that is responsible of whooping cough.
PTX belongs to the A-B structure class of bacterial toxins (205). Its B subunit binds to a
cell surface receptor, and the enzymatically active A subunit interrupts intracellular
signaling via irreversible ADP ribosylation of the Gi subclass of G protein (206). PTX
exerts its effects through binding to G protein coupled receptors, and since they are
present in several mammalian cell types, it affects most cells types (207). One of the Gi/o
protein dependent effects of PTX is lymphocytosis (208, 209). Moreover, PTX also acts
via a phosphokinase C pathway to increase the permeability of the blood-brain barrier
resulting in neurological effects (210). Studies have shown that PTX can trigger the
development of Th17 cells that promote inflammation (61, 64, 211). Today, PTX is also
recognized as a major contributor to autoimmune pathogenesis (212). Previous studies
have reported increased interferon gamma (IFN-γ) secretion by immune cells in response
to PTX (213), (214), (215). In addition, at the peak of B. pertussis infection, PTX
enhances neutrophil influx into the airways through the upregulation of interleukin-17
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(IL-17). Several studies comparing wild-type and PTX-deficient B. pertussis strains have
revealed that PTX plays an important role in promoting infection in the respiratory tract,
through initial phase of immune suppression followed by enhanced inflammation leading
to lung pathogenesis. Thus, agents that suppress inflammation induced by PTX may
serve as treatment modalities.
MicroRNAs (miRs) are short non-coding single stranded RNAs, about 19-25
nucleotides long, that negatively regulate the target genes expression at the post
transcriptional level (216, 217). A connection between microRNAs and different
diseases, such as inflammatory bowel disease, autoimmune diseases, and cancers, is
being investigated (216, 218, 219). Recent studies have shown that exposure to chemicals
can cause alteration in miRNAs and gene expression that lead to different health
problems and diseases (217, 220). The evidence linking between the environmental
chemical contaminants like dioxin and miRNAs functions to human diseases is rapidly
growing (221). However, it is not clear yet how AhR activation by TCDD alters miRNAs
or the possibility that TCDD-induced miRNAs may control mRNA that regulate
inflammation. Some studies have confirmed an association between deregulation of
miRNAs and exposure to environmental chemicals and the dioxins are among them
(222). It has been found that the toxic effects of TCDD may also be controlled by certain
epigenetic mechanisms like DNA methylation or histones modification (223). The
involvement of PTX in miRNAs dysregulation is also not fully understood and studies in
this field still limited. Ge et al. 2013, indicating that miR-202, 342-5p, 206, 487b, 576-5p
were upregulated and linked to the pathogenesis of inflammatory diseases and
significantly increased in the peripheral blood of pertussis patients (224, 225).
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In this study, we investigated whether AhR activation by TCDD can attenuate
PTX-induced inflammation in mice and if so, whether such anti-inflammatory action is
mediated by miRNA. Our studies demonstrate that TCDD does alter the expression of
several miRNA that target various cytokine and transcription factors in T cells leading to
suppression of PTX-mediated inflammation.
4.3 MATERIALS AND METHODS
Mice
Female C57BL/6 mice (6–8 weeks old) were purchased from Jackson
Laboratories (Indianapolis, Indiana). Animals were housed in AALAC approved animal
facility at the School of Medicine, University of South Carolina. Use of mice for
experiments and their maintenance were approved by the University of South Carolina
Institutional Animal Care and Use Committee.
Ethical statement
Animals used in the experiments of this study were approved by Institutional
Animal Use and Care committee of University of South Carolina.
PTX and TCDD Administration
TCDD was kindly provided by Dr. Steve Safe (Institute of Biosciences &
Technology, Texas A&M Health Sciences Center, College Station, Texas). TCDD
dissolved in DMSO (Sigma, St. Louis, MO) City, State?) was further diluted with corn
oil (CO), (Sigma. St. Louis, MO) before administration (212). The mice were first
injected intraperitoneal (ip) with vehicle (CO) or TCDD (25 µg/kg body weight) and
then injected intraperitoneal(ip) with 400 ng/mouse PTX (List Biological Laboratories,
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Campbell, CA) Twenty-four hours later, the mice were rechallenged with the same dose
of PTX, as described (16).
Determination of cytokines Expression by performing ELISA
To examine the expression of pro- and anti-inflammatory cytokines post PTX and
Vehicle or TCDD treatments, blood was collected from the portal vein of PTX+VEH and
PTX+TCDD mice. Sera from mice of both groups were either used immediately or stored
at -20 °C until further use. Cytokines of interest, such as IL-17A, IL-6, IFNγ and IL-10
were determined by performing ELISA using BioLegend ELISA Max kits (BioLegend,
San Diego, CA) and following the protocol of the company and as described in detail
previously by Busbee et al. (226).
Flow Cytometry Analysis of splenic cells post PTX and TCDD treatments
We performed flow cytometry to determine various cell types present in spleens
of mice treated with PTX + Vehicle and PTX+TCDD. In brief, single cell suspensions of
spleens from both groups were first prepared. The splenic cells were then treated with
GolgiPlug purchased from BD (BD Biosciences, San Jose, CA) for at least 6 hrs at 37°C
to enhance cytokine staining. These cells were then stained using PE-conjugated antimouse CD4 (clone GK1.5) for 30 min at 4°C. Next, the cells were washed with cold PBS
twice and then stained using following Abs: anti-FoxP3, anti-IL-10, anti-TGF-, anti-IL17, and anti-IFN- (Biolegend, San Diego, CA). For MDSCs, splenocytes were stained
with MDSCs fluorescent conjugated antibodies: CD11b and Gr-1. Stained cells were
analyzed using Beckman Coulter FC500 flow cytometer (Indianapolis, IN, USA) and
their software or BD FACSCelesta (BD Biosciences, San Jose, CA) and DIVA software
or FlowJo software.
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Investigation of miRNA profile in splenic CD4+ T cells
To investigate miRNAs profile in CD4+ splenic cells, CD4+ cells were isolated
from the splenocytes of PTX+VEH and PTX+TCDD groups of mice using the EasySep
PE Positive Selection Kit (StemCell Technologies, Cambridge, MA) and anti-CD4 mAb
(Biolegend, San Diego, CA). The isolated CD4 cells were washed with cold PBS and
then Qiazol Lysis Reagent (Qiagen, Germantown, MD) was added and either used
immediately for total RNA including miRNA or stored at -80°C for future use. Total
RNA including miRNAs were extracted using miRNeasy micro kit (Qiagen,
Germantown, MD) and according to the manufacturer’s instructions. The concentration
and purity of the extracted RNAs were determined using the NanoDrop 2000
spectrophotometer (Thermo Scientific, Wilmington, DE). The expression profile of
miRNAs was determined by performing microRNA Arrays using the Affymetrix miRNA
array version 4 (JHMI deep sequencing and microarray core) and GeneChip miRNA 3.0array platform. miRNAs data were analyzed using Inguinety Pathway Analysis (IPA,
Qiagen) as describe (227) . In this study, a > 1.5-fold change in miRNAs expression was
considered positive (228).
Validation of miRNAs in splenic CD4+ T cells treated with vehicle or TCDD
Next, we validated several of miRNA that were selected based on their expression
and corresponding genes expression. For miRNA expression analysis, cDNA synthesis
was performed from total RNA using miScript II cDNA Synthesis Kit (# 218161,
Qiagen, Germantown, MD). Two step miRNA qRT-PCR was carried out using
SsoAdvanced SYBR green Mix (#1725270 Bio-Rad, Hercules, CA) with mouse primers
for

SNORD96A

(#MS00033733

Qiagen,
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Germantown,

MD),

miR-141-3p

(#MS00001610 Qiagen, Germantown, MD), miR-142-3p (# MS00012201 Qiagen,
Germantown, MD), and miR-211-3p (# MS00024563 Qiagen, Germantown, MD).
Expression levels for miRNA were normalized to SNORD96A. All PCR experiments
used a CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA). Fold
changes were calculated using the 2−ΔΔCT method.
Validation of miRNAs-specific gene expression in splenic CD4+ T cells treated with
vehicle or TCDD
Next, we evaluated the expression of target genes (IL-10, TGF-β1, TGFβ2,
TGFβR3, TGFβR1, GATA3, SMAD2, IL-6, and RORγt), as described (229). For gene
expression analysis, cDNAs was generated as described above from total RNA using
miScript II cDNA synthesis kit. A two-step amplification with a 60° annealing
temperature for qRT-PCR was carried out using SsoAdvanced SYBR green supermix
from Bio-Rad with mouse primers for IL-10, TGF-β1, TGFβ2, TGFβR3, TGFβR1,
GATA3, SMAD2, IL-6, and RORγt customized and ordered from IDT (Coralville,IA).
All PCR experiments used a CFX96 Touch Real-Time PCR Detection System (Bio-Rad,
Hercules, CA), and expression levels were normalized to GAPDH mRNA levels. Fold
changes were calculated using the 2−ΔΔCT method.
Transfection of splenic cells with miR-1224-5p and miR-3082-5p mimic or inhibitor
Two miRNAs (miR-3082-5p and miR-1224-5p) were selected based on their
alignments with mouse IL-17 and FoxP3 genes. For transfection, we used T cells purified
from naïve splenocytes and maintained for 24 hours in complete RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum, 10 mM L-glutamine, 10
mM HEPES, 50 μM β-mercaptoethanol, and 100 μg/ml penicillin/streptomycin at 37°C
and 5% CO2 (32). Prior to transfection, T cells were seeded at a density of
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2x105 cells/well in a 24-well plate. The following day, the cells were transfected with
scrambled miRNA (Mock) control or mature miR-1224-5p mimic (Qiagen #
MSY0005460), miR-1224-5p inhibitor (Qiagen # MSY0005460), mature miR-3082-5p
mimic or miR-3082-5p inhibitor (Qiagen # YI04103580) using HiPerFect transfection
reagent (Qiagen, Germantown, MD) and following the protocol of the company.
Quantitative Real-Time PCR (qRT-PCR) to determine the expression of miRNAs
and target genes
We performed Q-RT-PCR to determine the expression of miRNAs that target
FoxP3 and IL17 genes respectively. The selection of these two miRNAs was based on
their alignment with highly conserved regions of their target genes using miRNA.org,
miRNAWalk, TargetScan software. As described above, cDNA synthesis was performed
from total RNAs using miScript II cDNA Synthesis Kit (Qiagen # 218161) and Two step
miRNA QRT-PCR were carried out using SsoAdvanced SYBR green Mix (BioRad
#1725270) with mouse primers for SNORD96A (Qiagen #MS00033733), miR-3082-5p
(Qiagen # MS00025102), miR-1224-5p (Qiagen # MS00011074), Expression levels for
miRNAs were normalized to SNORD96A. All PCR experiments used a CFX96 Touch
Real-Time PCR Detection System (Bio-Rad. Fold changes were calculated using the
2−ΔΔCT method.
Next, we evaluated the expression of target genes (FoxP3 and IL17) by
performing QRT-PCR as described above.

All qRT-PCRs were performed using a

CFX96 Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA), and
expression levels were normalized to GAPDH mRNA levels. Fold changes were
calculated using the 2−ΔΔCT method. Specific primers sequences of genes are provided in
table 2. Furthermore, we also performed QRT-PCR to determine the expression of miR84

3082-5p and miR-1224-5p and their respective target genes IL17 and FoxP3 in miR3082-5p and miR-1224-5p mimic and inhibitor-transfected T cells treated with
PTX+Vehicle and PTX+TCDD as described above.
Statistical analysis
We used GraphPad Prism6 software to perform statistical analyses. The statistical
analyses were performed using Student’s t-test and/or ANOVA. p value <0.05 was
considered significant.
4.4 RESULTS
TCDD suppresses PTX-induced inflammation in mice
In this study, we investigated the effect of AhR activation by TCDD on PTXmediated inflammatory response in C57BL/6 mice. To that end, mice received
PTX+TCDD or PTX+Veh on day 0 and 24 hr later, all mice received a second dose of
PTX. On day 4, the mice were euthanized and studied for inflammation (Fig 1A). First,
we performed ELISA using sera from PTX+VEH and PTX+TCDD groups. The data
showed significant decrease in pro-inflammatory cytokines IL-17A, IFN-γ, and IL-6 in
PTX+TCDD mice, when compared to PTX+VEH mice (Figure 1B-D). In contrast, there
was significant increase in IL-10, an anti-inflammatory cytokine in PTX+TCDD group,
when compared to PTX+VEH group (Figure 1E). These data demonstrated that TCDD
may suppress pro-inflammatory cytokine response by upregulating the generation of antiinflammatory cytokine, IL-10.
TCDD promotes differential regulation of Tregs and Th17 cells and generation of
MDSCs in vivo
Next, we investigated the phenotypic changes in spleens harvested from
PTX+VEH and PTX+TCDD mice. We analyzed for the following cell types: Tregs:
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CD4+FoxP3+, Th17: CD4+IL17+, Th1: CD4+IFNγ+, and Th2:CD4+IL10+ and
CD4+TGFβ+ cells. When we compared Th1 vs Th2 cells, we noted that the percentages
of Th2 cells (CD4+IL10+ cells and CD4+TGFβ+) were significantly increased in
PTX+TCDD group, when compared to PTX+VEH group (Figure 2A, B). In contrast, the
proportions of Th1 cells was significantly decreased in PTX+TCDD group when
compared to controls (Figure 2 C). Th17 and Tregs are reciprocally regulated and thus
when we analyzed these cells in the two groups and found that the percentages of Th17
cells (CD4+IL17+) were increased while that of Tregs (CD4+FoxP3+) were decreased in
PTX+VEH group and interestingly, this pattern was completely reversed in PTX+TCDD
group (Figure 3 A, B).
We also examined myeloid-derived suppressor cells (MDSCs; CD11b+/Gr1+) in
spleens of PTX+VEH and PTX+TCDD groups of mice because these cells are also
highly immunosuppressive and have been known to induce Tregs (230), (231). There
was significant increase in both the percentage and numbers of MDSCs in the mice
exposed to PTX+TCDD group when compared to controls (Figure 4A-C).
TCDD dysregulates expression of miRNAs in splenic cells in vivo
To understand anti-inflammatory/immunosuppressive effects of TCDD, we
investigated the molecular mechanisms that TCDD may regulate to affect gene
expression. To this end, we performed miRNA arrays using total RNA from splenic
CD4+ T cells from PTX +VEH and PTX+TCDD groups as described in Methods. Of
approximately 1111 miRNAs tested, 157 miRNAs were differentially expressed (Fold
change > +/- 1.5) (Figure 5A). Proportional Venn diagram was generated to represent the
fold change Of 1111 miRNA in CD4+ T cells examined, there were 48 miRNA that were
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upregulated (>1.5-fold) and 58 miRNA that were downregulated (>1.5-fold) in splenic
CD4 T cells of PTX+TCDD group of mice, when compared to PTX+VEH group of mice
(Figure 5B). Next, 106 miRNA that showed altered expression in PTX+TCDD group
were analyzed using Ingenuity Pathway Analysis (IPA) software from QIAGEN. IPA
pathway analysis showed several miRNAs that targeted the expression of cytokines,
transcription factors, and signaling molecules related to inflammation (Figure 5C). Using
Affymatrix Expression Console software, heat map of miRNAs of both groups was
generated (Figure 5D). In addition, we analyzed miRNA-specific target genes using
TargetScan and microRNA.org (www.microRNA.org) analytical tools available online.
A list of target genes and their putative 3’UTRs (mRNAs/miRNAs) has been presented in
Table 3. We identified miR-142-3p to target FoxP3, TGFβ2 and TGFβR1, miR-141-3p to
target TGFβ2 and TGFβR1, miR-211-3p to target TGFβ1, TGFβ2, TGFβR1 and Smad2
(Table 3). These data suggested that TCDD causes dysregulation of miRNA in T cells
that target genes involved in inflammatory pathways.
Validation of miRNAs by Quantitative Real-Time PCR (QRT-PCR)
After analyzing miRNAs profile obtained from miRNA arrays, we selected
several miRNAs, particularly that target cytokines production and Tregs proliferation, to
validate their expression by QRT-PCR. We used the same RNAs from CD4+ T cells that
we used for miRNA arrays. We validated the microarray data by using QRT-PCR of
some select miRs that were up or down-regulated following TCDD treatment. The data
demonstrated that there was significant downregulation, miR-141-3p (Figure 5E,
miR142-3p (Figure 5F), and miR-211-3p (Figure 5G) in splenic CD4 T cells from
PTX+TCDD group when compared to PTX+VEH group.
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qRT-PCR to determine the expression miRNA target genes
Next, we validated the gene expression of some of the targets of miRs disrupted
by TCDD.

We noted significant upregulation of IL-10 (Figure 6A), TGF-β1 (Figure

6B), TGF-β2 (Figure 6C), TGF-βR3 (Figure 6D), TGF-βR1 (Figure 6E), GATA3 (Figure
6F), SMAD2 (Figure 6G) in cells from mice exposed to PTX+TCDD, when compared to
PTX+VEH group. Additionally, there was significant downregulation of IL-6 (Figure
6H), and RORγT (Figure 6I) in PTX+TCDD group when compared to PTX+VEH group.
Transfection studies to demonstrate the specificity of miR and their inflammatory
target genes.
During IPA analysis and using target scan, we observed that miR-1224-5p and
miR-3082-5p had strong binding affinity with 3’UTRs of FoxP3 and IL-17, respectively
(Table 3). To confirm that miR-1224 and miR-3082 specifically targeted FoxP3 and IL17 gene expression, respectively, we first performed QRT-PCR analysis of the expression
of both miRs and potential targets from the same cell population namely, splenic CD4+
cells from PTX+VEH or PTX+TCDD. We noted significant upregulation of miR-30825p (Figure 7A) and downregulation of miR-1224 (Figure 7E) in PTX+TCDD group when
compared to controls.

Additionally, in the same cells, there was significant

downregulation of IL-17 expression (Figure 7B) and increase in FoxP3 expression
(Figure 7F) in PTX+TCDD groups when compared to controls. These data demonstrated
that in the same cells, the miRNA expression induced by TCDD correlated with the
expression of respective target genes involved in inflammation.
To further confirm the role of miR-1224-5p and miR-3082-5p in the regulation of
FoxP3 and IL-17, respectively, CD4+ T cells were transfected with either miR-1224-5p
or miR-3082-5p mimics or their respective inhibitors. Expression of miR-1224-5p and
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miR-3082-5p was determined by QRT-PCR. There was significant increase in the
expression of miR-3802-5p and miR-1224-5p in cells transfected with miR-3082-5p
mimic or miR-1224-5p mimic when compared to mock controls (Figure 7C, G).
Inhibitors of miR-3082-5p and miR1224-5p completely blocked the expression of these
miRs respectively (Figure 7C, G). In these cells, transfection with miR-3082-5p mimic
led to significant downregulation of IL-17 while the inhibitor caused upregulation of IL17 (Figure 7D). Furthermore, transfection of these cells with miR-1224-5p mimic led to
downregulation of FoxP3 while the inhibitor caused increased expression of FoxP3
(Figure 7H). The data obtained from transfection experiment demonstrated a clear role of
miR-1224-5p and miR-3082-5p in the expression of FoxP3 and IL-17 mediated by
exposure to TCDD.
4.5 DISCUSSION
Bordetella pertussis is a human respiratory pathogen that causes whooping
cough, and its virulence factor, pertussis toxin (PTX), promotes colonization leading to
systemic disease (232). Experimentally, PTX is well characterized as an adjuvant that
promotes development of tissue-specific experimental autoimmune diseases such as
experimental autoimmune encephalomyelitis (EAE), experimental autoimmune uveitis
(EAU), and the like (233),(234). PTX in these models, is known to enhance vascular
permeability, damage to blood-brain barrier and induce Th1 responses (235), (236). More
recent studies suggested that PTX can induce a robust Th17 response while inhibiting
Tregs (64). While the precise mechanisms through which PTX serves as a virulence
factor in promoting B. pertussis infection is unclear, it is believed that the ability of PTX,
at peak of B. pertussis growth in the airways, to trigger increased inflammation leads to

89

pathology in the airways(60). Thus, agents that suppress such inflammation induced by
PTX may help attenuate the pathogenesis. In the current study, therefore, we tested the
effect of TCDD, a potent AhR ligand on PTX-mediated inflammation. Because the
effect of TCDD on a potent toxin such as PTX known for its ability to promote Th1 and
Th17 response while suppressing Tregs, has not been studies previously, we were
interested to see if TCDD would reverse these effects and if so, identify the mechanisms.
TCDD is described as the worst and most toxic human made environmental
contaminant. TCDD is an environmental pollutant that mediates toxicity through
activation of AhR, a ligand-dependent transcription factor and member of the basic helixloop-helix–Per/Arnt/Sim gene family (237, 238). It is well characterized for its toxicity
against the cells of the immune system (239-241). More recently, activation of AhR by
TCDD has been shown to regulate differential expression of FoxP3 and IL-17 causing
generation of more Tregs but suppression of Th17 cells (239), (242). The study from our
lab has shown that TCDD suppressed EAE in mice (212). We have shown that TCDD
modulated differential expression of IL-17 and FoxP3 in mice with EAE through
epigenetic modifications (212). PTX, on the other hand, has been shown to promote the
generation of Th17 cells (64). Because of opposite molecular functions of PTX and
TCDD, we investigated whether TCDD can suppress PTX-induced inflammation in mice
and examined the molecular mechanisms involved in TCDD-induced suppression of
PTX-induced inflammation.
In this study, we noted that injection of PTX triggered significant systemic
inflammation in mice as evidenced by detection of several inflammatory cytokines in the
serum including IL-17, IL-6, and IFN-γ. These cytokine expressing cells were also
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detected in CD4+ T cells in the spleen. Interestingly, the serum levels of IL-17 or
proportion of Th17 cells in the spleens of PTX-treated mice was higher than that of IFN-γ
or Th1 cells in the spleen, thereby demonstrating that PTX is a more potent inducer of
Th17 cells than Th1 cells. These data were consistent with the observation that PTX
generates a cytokine storm associated with inflammation in mice by inducing IL-6 that
promotes IL-17 production in CD4+ T cells (64). Also, our findings agree with previous
observation that administration of PTX stimulates the development of pathogenic Th17
cells in mice of immune-mediated ocular inflammation more than other TLR ligands,
such as LPS, and polyinosinic-polycytidylic acid (243). In another study, it was reported
that immunization with whole cell pertussis vaccination in mice resulted in the generation
of Th17 cells (244). Previous studies, using mice infected with pertussis toxin (PTX)–
producing B. pertussis strain or an isogenic PTX-deficient strain (ΔPT), had shown that
PTX activity was associated with upregulated expression of proinflammatory cytokines
and chemokines (61) (232). Studies on immunomodulation by B. pertussis have also
shown that the host immune response may be tilted towards development Th17 cells, that
produce IL-17A (64).
In the current study, we noted that TCDD caused significant decrease in
inflammatory (IL-17, IL-6, and IFN-γ) cytokines but an increase in anti-inflammatory
(IL-10) cytokine in PTX-injected mice. These data demonstrated that TCDD was able to
suppress PTX-induced inflammation in mice. We noted increased switch from Th1 to
Th2 phenotype with increased induction of IL-10 and TGF-

following TCDD

treatment. IL-10 is an anti-inflammatory cytokine that is known to inhibit the activity of
Th1 cells (245). TGF-

inhibits Th1 differentiation by blocking the expression of T-
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bet, the master regulator of Th1 cell differentiation (246). We also noted that TCDD was
able to induce a switch from Th17 to Tregs in PTX-immunized mice. This may result
from decreased IL-6 seen in PTX+TCDD treated mice because IL-6-mediated STAT3
signaling is essential for Th17 differentiation and plays a central role in the pathogenesis
of certain autoimmune diseases such as rheumatoid arthritis (247).

The second

mechanism through which TCDD may suppress Th17 cells may result from its ability to
increase the expression of FoxP3 and induce more Tregs as seen in the current study
using PTX and seen in other models autoimmune disease (248), (249). For example,
TCDD was shown to suppress diabetes in NOD mice by increasing Foxp3+ T cells in
pancreatic lymph nodes (249). Also, TCDD inhibited the clinical symptoms in an
experimental autoimmune encephalomyelitis (EAE) model by inducing Tregs (68).
Because EAE mouse models use PTX along with myelin oligodendrocyte glycoprotein
(MOG) to enhance clinical signs of EAE, our studies raise an interesting question on
whether TCDD-mediated suppression of EAE results from suppression of PTX effects or
direct action on MOG-specific T cells. Previous studies from our laboratory has also
shown that activation of AhR led to reciprocal epigenetic regulation of FoxP3 and IL-17
expression and amelioration of experimental Colitis (239). In this study, we noted that
there was decreased methylation of CpG islands of Foxp3 and increased methylation of
IL-17 promoters, which led to increased induction of Tregs while suppressing Th17
generation (239). In the current study, we noted that TCDD induced MDSC in PTXtreated mice. Because Tregs have also been shown to be induced by MDSCs
30103447,(250) this may constitute another additional mechanism through which Tregs
were induced in PTX+TCDD administered mice. As there were more Tregs in
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PTX+TCDD-treated mice, it is possible that the increased IL-10 seen in these mice may
have resulted from such Tregs that produce IL-10 (251). Previous studies from our lab
reported TCDD-induced MDSCs generation in different tissues/organs like spleen and
peritoneal cavity. Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous
population of immature myeloid cells that play a major role in immunosuppression in
inflammation, cancer, and other diseases (252).
In recent years, miRs have been shown to play an important role in the regulation
gene expression and potentially may control majority of the molecular and cellular
pathways (253-255). Also, specific miRs may play important roles in T cell and MDSCs
development and functions by regulating target genes involved in their proliferation and
differentiation (230). Previous studies from our lab have shown that AhR activation by
dietary ligands such as indole-3-carbinol (I3C) or 3,3'-diindolylmethane (DIM) leads to
decreased the expression of several miRs (miR-31, miR-219, and miR-490) that target
Foxp3, while incresinga the expression of miR-495 and miR-1192 that target IL-17 (240).
This leads to increased induction of Tregs and decreased differentiation of Th17 cells
consequently suppressing delayed-type hypersensitivity (DTH) response to methylated
BSA (240)

In another study, we noted that miRNA-466a-3p targeted TGF-β2 and

regulated Treg differentiation (256). In the current study, we observed that PTX+TCDD
group showed significant alterations in the expression of a numbers of miRNA and
pathway analysis showed that some of these altered miRNAs targeted inflammatory
cytokines or signaling pathways. Interestingly, we were able to narrow down to some
specific miRs that seemed to target FoxP3 and IL-17 gene expression through target
scanning. Specifically, we found that miR-1224-5p and miR-3082-5p had strong binding
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affinity with 3’UTRs of FoxP3 and IL-17, respectively. We confirm the role of miR1224-5p and miR-3082-5p in the regulation of FoxP3 and IL-17, respectively, we
performed transfection studies which conclusively demonstrated that miR-1224-5p and
miR-3082-5p were involved in the upregulation of FoxP3 and down regulation of IL-17
following exposure to TCDD. The role of miR-1224-5p in the regulation of immune
response has not been previously studied. MiR-1224-5p has been shown to act as a tumor
suppressor by targeting CREB1 in malignant gliomas (257). Similarly, the role of miR3082-5p has not been reported in any disease model. Thus, our studies are unique in
identifying for the first time that miR-1224-5p and miR-3082-5p play a role in the
regulation of inflammation.
In summary, our studies suggest that during PTX-induced inflammation,
activation of AhR by TCDD may promote anti-inflammatory activity primarily through
regulation of miRNA that target Foxp3 and IL-17 gene. Because PTX plays a critical
role in the pathogenesis of B. pertusis infection by inducing cytokine storm and
exaggerated inflammatory response, our studies suggest that AhR ligands may serve as
therapeutic modality to treat such inflammatory response
.

94

Figure 4.1 TCDD suppresses PTX-induced inflammation in mice. Mice were injected
with PTX and TCDD as described in panel A and 4 days later, PTX+VEH or
PTX+TCDD groups were investigated for inflammation. (B) ELISA was performed
using sera collected from PTX+VEH and PTX+TCDD group of mice. Cytokines IL-17A
(B), IL-6 (C), IFNγ (D), and IL-10 (E) were measured. Data are expressed as the mean ±
S.E.M. and statistical significance is indicated as **p < 0.01, ***p< 0.001 and ****P <
0.0001 between the two groups.
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Figure 4.2 TCDD suppresses PTX-induced Th1 cells and promotes Th2 cells. Mice
were immunized with PTX and injected with TCDD as described in Fig 1 legend.
Splenocytes were double-stained for CD4 and various cytokines and analyzed by flow
cytometry: (A) IL-10; (B)TGF-β; (C) IFN- . Panels A-C show a representative
experiment and data from multiple mice plotted in Panel D. Statistical analysis using
Student’s t-test. Data are expressed as the mean ± S.E.M. and statistical significance
between the two groups is indicated as *p < 0.05.
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Figure 4.3 TCDD promotes Treg while inhibiting Th17 induction. Mice were
immunized with PTX and injected with TCDD as described in Fig 1 legend. Splenocytes
were double-stained for CD4 and FoxP3 or CD4 and IL-17 markers and analyzed using
Flow cytometry. Panel A shows a representative experiment while data from multiple
mice plotted in Panel B, showing reciprocal regulation of Th17 vs Tregs between the two
groups. Statistical analysis between the two groups showing ****p < 0.0001.
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Figure 4.4 TCDD promotes MDSCs production. Mice were immunized with PTX and
injected with TCDD as described in Fig 1 legend. Spleen cells were double-stained for
Gr-1+CD11b+ cells. Panel A shows a representative experiment while data from
multiple mice is plotted in Panel B-C. Statistical analysis using Student’s t-test. In Panel
B-C data are expressed as the mean ± S.E.M. and statistical significance is indicated as
****p < 0.0001 when the two groups are compared.
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Figure 4.5 MicroRNAs Analysis. Mice were immunized with PTX and injected with
TCDD as described in Fig 1 legend. Differentially expressed miRNA were analyzed in
splenic CD4+ T cells. Total RNA was isolated and pooled from CD4+ T cells obtained
from the spleen of PTX+VEH or PTX+TCDD groups (n = 5). miRNA microarray assay
was performed to test differentially expressed miRNA. (A) The fold change distribution
of the miRNAs found within CD4+ T cells from the spleen of PTX+Vehicle and PTX
+TCDD mice. (B) Proportional Venn diagram illustrating fold change (>1.5) of miRNAs
between the two groups. (C) Pathway analysis of miR mediating dysregulation in gene
expression in PTX+TCDD group. (D) Heat map of hierarchical clustering of the relative
expression of miRNA alterations. The color scale denotes those miRNAs that were
upregulated (red) and downregulated (green). (E-G) Expression levels of select
downregulated miRNAs analyzed by qRT-PCR using Snord96a as a control.
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Figure 4.6 qRT-PCR validation of gene expression. Mice were immunized with PTX
and injected with TCDD as described in Fig 1 legend. Expression of target genes was
studied using qRT-PCR in CD4+ Tcells: (A) IL-10, (B) TGF-β1, (C)TGFβ2,
(D)TGFβR3, (E) TGFβR1, (F) GATA3, (G) SMAD2, (H) IL-6 and (I) RORγt are
shown, using GAPDH as a control. Data present mean ±SEM of 3 tests and statistical
significance between the two groups was tested by Student’s t-test and p values were
indicated as follows: *p < 0.05; **p < 0.01 and ****p< 0.000.
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Figure 4.7 Role of miR-3082-5p and miR-1224-5p in regulating expression of IL-17A
and FoxP3 respectively. T cells purified from splenocytes were analyzed as described in
Fig 6: (A, B, E, F): miRNA and target gene expression were analyzed by qRT-PCR. For
transfection studies (C, D, G, H), splenic T cells were purified from naive B6 mice were
cultured for 24 h transfected by nucleofection with miR-3082 inhibitor or mimic, and the
expression of miRNA and target genes was analyzed using qRT-PCR. Data are presented
as the mean ±SEM. Of experiments performed 3 times. Statistical significance between
the two groups was compared by Student’s t-test with p values indicated as follows: *p<
0.05, **p< 0.01, **p< 0.001 and ****p< 0.0001.
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Table 4.1 Up-regulated and down-regulated miRNAs upon TCDD exposure
microRNA Identification
miR-211-3p
miR-142-3p
miR-141-3p
miR-3082-5p
miR-1224-5p

microRNA Sequence (5'-3')
GCAAGGACAGCAAAGGGGGGC
UGUAGUGUUUCCUACUUUAUGGA
UAACACUGUCUGGUAAAGAUGG
GACAGAGUGUGUGUGUCUGUGU
GUGAGGACUGGGGAGGUGGAG
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Table 4.2 mRNA related oligonucleotides that used in this study
Gene

Forward Sequence (5′–3′)

Reverse Sequence (5′–3′)

Tgfβ1 CTCCCGTGGCTTCTAGTGC

GCCTTAGTTTGGACAGGATCTG

Tgfβ2 CTTCGACGTGACAGACGCT

GCAGGGGCAGTGTAAACTTATT

Tgfβr1 TCTGCATTGCACTTATGCTGA

AAAGGGCGATCTAGTGATGGA

Tgfβr3 GGTGTGAACTGTCACCGATCA

GTTTAGGATGTGAACCTCCCTTG

Il10 CCCATTCCTCGTCACGATCTC

TCAGACTGGTTTGGGATAGGTTT

Foxp3 CCCATCCCCAGGAGTCTTG

ACCATGACTAGGGGCACTGTA

Smad2 ATGTCGTCCATCTTGCCATTC

AACCGTCCTGTTTTCTTTAGCTT

Gata3 CTCGGCCATTCGTACATGGAA

GGATACCTCTGCACCGTAGC

IL17a TTTAACTCCCTTGGCGCAAAA

CTTTCCCTCCGCATTGACAC

RORγt GACCCACACCTCACAAATTGA

AGTAGGCCACATTACACTGCT

Il6

CTGTTGTTCAGACTCTCTCCCT

CCAAGAGGTGAGTGCTTCCC

GAPDH TGGATTTGGACGCATTGGTC
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TTTGCACTGGTACGTGTTGAT

Table 4.3 3’UTR alignments and scores of miRNAs and their target genes
IL-17A
5' ...AUAAUUUAGCUCCCUACUCUGUU...
|||||||
UGUGUCUGUGUGUGUGAGACAG

3'

(Position 585-591)

mmu-miR-3082-5p

Targetscan

context++ score: -0.26

Targetscan context++ score percentile: 97

IL-17AR
5' ...GAGGGUGUAUAUUGUACUCUGUG...
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3'

|||||||
UGUGUCUGUGUGUGUGAGACAG

(Position 38-44)

mmu-miR-3082-5p

Targetscan

context++ score: -0.04

Targetscan context++ score percentile: 81

FoxP3
5' ...CAUGAUAGUGCCUGUGUCCUCAA... (Position 1529-1536)

3'

|||||||
GAGGUGGAGGGGUCAGGAGUG

3'

agguauuucauccuuuGUGAUGu 5'

|||||||
1737:5' gccauucccccuuuucCACUACu 3'

mmu-miR-1224-5p

mmu-miR-142-3p

FoxP3

Targetscan

context++ score: -0.16

Targetscan context++ score percentile: 91

mirSVR score: -0.0083

PhastCons score: 0.4973

TGFβ1
5' ...GUCAGGUGUGUGGCUGUCCUUGA... (Position 1529-1536)
||||||||||
CGGGGGGAAACGACAGGAACG

3'

mmu-miR-211-3p

Targetscan

context++ score: -0.03

Targetscan context++ score percentile: 68

TGFβR1
5' ...UGACAUUUUUCCACUUCCUUGAG...

3'

||||||
CGGGGGGAAACGACAGGAACG

(Position 1529-1536)

mmu-miR-211-3p
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5' ...UUAAAUUUCAUCCUAACACUACA... (Position 1529-1536)

3'

|||||||
AGGUAUUUCAUCCUUUGUGAUGU

mmu-miR-142-3p

5' ...UUUAUUUGAUCAAAGCAGUGUUU... (Position 1050-1056)

3'

|||||||
GGUAGAAAUGGUCUGUCACAAU

mmu-miR-142-3p

Targetscan

context++ score: - 0.02

Targetscan context++ score percentile: 45

Targetscan

context++ score: - 0.44

Targetscan context++ score percentile: 95

Targetscan

context++ score: - 0.47

Targetscan context++ score percentile: 98

TGFβ2
5' ...GGAGUUUUGAUUCAUCAGUGUUU... (Position 106-112)

Targetscan

context++ score: - 0.3

3'

|||||||
GGUAGAAAUGGUCUGUCACAAU

mmu-miR-141-3p

5' ...CUAGAUUUUGACUUGCACUACAA...(Position 1222-1228)

3'

||||||
AGGUAUUUCAUCCUUUGUGAUGU mmu-miR-142-3p

5' ...CUUAUCUGAGGAGCUGUCCUUGA.. (Position 2098-2105)

3'

||||||||||
CGGGGGGAAACGACAGGAACG

mmu-miR-211-3p

Targetscan context++ score percentile: 93

Targetscan

context++ score: - 0.17

Targetscan context++ score percentile: 76

Targetscan

context++ score: - 0.13

Targetscan context++ score percentile: 89
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Smad2
5' ...UGGAUUAACUUGGAAGUCCUUGA... (Position 581-588)

3'

|||
|||||||
CGGGGGGAAACGACAGGAACG

mmu-miR-211-3p

Targetscan

context++ score: - 0.15

Targetscan context++ score percentile: 91

CHAPTER 5
SUMMARY AND CONCLUSION
Inflammation is involved in the pathogenesis of several clinical disorders
including autoimmune, cardiovascular, and neurological diseases, obesity and cancer.
Thus, identifying agents that suppress inflammation can have significant impact on
human health. In the current study, we used two unique models of inflammatory disease:
1) Chronic inflammatory mouse model of EAE that mimics human MS, and 2) Acute
mouse model of inflammation using PTX, a toxin produced by Bordetella pertussis that
causes whooping cough. In these models, we tested the role of activation of CB receptors
and AhR, using select agonists such as cannabinoids (THC and CBD), or TCDD,
respectively, to suppress inflammation. THC+CBD combination (Sativex) has been used
to treat patients with MS for muscle spasticity. However, whether it can also suppress
neuro-inflammation and if so, the mechanism of action remains obscure. We demonstrate
the effectiveness of these cannabinoids to ameliorate chronic inflammation, through
unique mechanisms. The current study demonstrates for the first time that THC+CBDmediated suppression of neuroinflammation in EAE stems from alterations in miRNA
expression and changes in microbiota.

Specifically, THC+CBD reduced cellular

infiltration into the brain and spinal cord, decreased pro-inflammatory cytokines such as
IL-17A, IFNγ, IL-6, TNF-α and IL-1β levels, while increasing anti-inflammatory IL-10
and TGF-β. Also, THC+CBD prevented T cell expansion through induction of cell cycle
arrest and apoptosis. Collectively, we showed that the combination of THC and CBD
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suppresses neuro-inflammation and that this may be regulated by certain miRNA as well
as alterations in the gut microbiota. Importantly, these studies form the basis of targeting
such miRNA and microbiota to treat MS. We also demonstrated that AhR activation by
TCDD led to suppression of acute inflammation induced by Pertussis Toxin (PTX). PTX
is an exotoxin that promotes bacterial invasion into the lungs and cause lung toxicity.
Such toxicity results from cytokine storm involving pro-inflammatory cytokines such as
IL-17A, IFNγ, and IL-6. AhR activation decreased the production of these cytokines
potentially through induction of immunosuppressive cells such as Tregs and MDSCs.
AhR activation was also associated with alterations in the expression of miRNAs that
promoted anti-inflammatory pathways.

It is interesting that activation of both CB

receptors and AhR caused alterations in the expression of miRNA that targeted antiinflammatory pathways. Thus, the current study, by using CB and AhR signaling
pathways, has identified new epigenetic pathways that can be targeted to suppress
inflammation and thus treat inflammatory diseases.
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